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ABSTRACT 
 
 
Regulation of bone formation and pathology by local actions of leptin in the bone 
marrow 
 
by 
 
Erica L Scheller 
 
 
Chair: Paul H Krebsbach 
 
Site-specific adipose content of the bone marrow has been noted since the inclusion 
of meat into the hominid diet, evidenced by marrow removal from ungulate limb 
bones, 2.6 million years ago.  Association between marrow fat and bone metabolism 
has since been documented, however the mechanism for this relationship remains 
unknown.  Leptin, a secreted adipocytokine, possesses the ability to regulate bone 
formation both centrally through the hypothalamus and peripherally though marrow 
cells such as the osteoblast.  Until the recent generation of a mouse with loxP sites 
flanking exon17 of the signaling-competent leptin receptor (ObRb), the physiologic 
contribution of peripheral leptin signaling to bone formation could not be determined.  
Leptin has been shown to increase mineralization of primary bone marrow stromal 
precursor cells (MPCs) and osteoblasts in vitro.  Leptin is also a potent regulator of 
pro-inflammatory macrophage cytokine output.  We therefore examined the ability of 
leptin to modulate bone formation through the myeloid lineage, the osteoblast, and 
the MPC by generating mice with conditional deletion of ObRb using LysozymeM 
 ix 
(LysM), Col2.3, and Col3.6 promoters driving Cre recombinase respectively.  
Myeloid-specific deletion of ObRb resulted in a mild, gender-specific bone 
phenotype in 52 week old animals with decreases in trabecular parameters noted in 
females and increases in cortical values in males.  This change mimics associations 
between circulating leptin and bone mineral density (BMD) observed in adult 
humans.  Osteoblast ObRb deletion using Col2.3-Cre did not produce a discernable 
bone phenotype.  However, conditional removal of ObRb with Col3.6-Cre on more 
primitive MPCs increased femoral length and trabecular and cortical femoral 
parameters at 12 and 52 weeks of age.  Our results imply that at physiologic 
equilibrium, leptin regulation of mature osteoblast function is negligible, however, 
early modulation of MPCs may contribute to properties such as bone length and 
trabecular formation.  In contrast, regulation of myeloid lineage cells such as 
macrophages may explain adult gender-specific differences in associations between 
circulating leptin and BMD.  Further modulation of macrophage-associated leptin 
signaling by compounds such as amino-bisphosphonates may enhance the ability of 
leptin to contribute to bone formation as well as the pathogenesis of diseases such as 
osteonecrosis of the jaw.                 
 1 
CHAPTER 1 
 
INTRODUCTION 
 
1.1 Exploring the role of adipose in the bone marrow 
Largely due to the use of marrow as a food source, it has long been recognized that bone 
marrow composition varies by site with the more red marrow being confined toward the 
middle of the animal and the yellow, or fatty, marrow existing toward the periphery.  
Indeed, the initial inclusion of meat into the hominid diet 2.6 million years ago was 
inferred due to evidence of bone marrow removal shown by impact fractures from stone 
tools on sections of ungulate limb bones (Krech, McNeill et al. 2004).  We have since 
learned that the functions of the adult bone marrow include blood cell formation, or 
hematopoiesis, and maintenance of skeletal structure through precise regulation of bone 
turnover and metabolism. Though osteoblasts and osteoclasts are recognized as the 
primary mediators of bone turnover, it is now appreciated that over thirty distinct cell 
populations reside in close proximity to the bone lining cells (Metcalf 2007; Phinney and 
Prockop 2007).  These include hematopoietic lineage cells, mesenchymal lineage cells 
such as adipocytes, blood vessels, and neural tissue.  Each of these cell populations, alone 
or in combination, may possess the capacity to influence bone growth and regeneration.  
This dissertation will focus on the contribution of the adipocyte to bone metabolism and 
pathology in the context of the secreted adipocytokine leptin. 
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Site specific differences in marrow adipose content are best illustrated in the vertebral 
column of rodents where marrow fat content increases as one progresses toward the tail 
(Figure 1).  This initial observation of the bone marrow adipose transition in the caudal 
vertebrae of rats was made by Ranvier in Paris in 1889 (Ranvier 1889; Huggins and 
Blocksom Jr 1936).  In addition to site-specific differences in marrow content, the 
number of fat cells present in the skeleton varies depending on age of the host, obesity, 
exogenous treatment, or disease state.  For example, irradiation of the bone at a dose 
designed to prepare the host for a bone marrow transplant results in a transient filling of 
the bone cavity with adipose tissue for one to two weeks (Naveiras, Nardi et al. 2009).  
Alternatively, inhibition of expression of secreted adipocytokines such as leptin results in 
a robust accumulation of marrow fat in the distal femur (Hamrick, Pennington et al. 
2004) (Figure 2).  Though the presence of marrow fat appears to be tightly controlled, we 
do not yet understand its role or if the segregation of red and yellow marrow has any 
significance.   
 
Figure 1.  Bone marrow adipose transition from thoracic to caudal vertebrae in mouse.  Credit: Reprinted 
by permission from Macmillan Publishers Ltd: Nature (Naveiras, Nardi et al. 2009), ©2009 
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Figure 2. Leptin-deficient ob/ob mice have increased marrow fat in the distal femur but not in the lumbar 
vertebrae.  4x magnification.  WT: wild type.  Credit: E.L Scheller, unpublished data. 
Since the formal description of marrow adipose site specificity in 1889 (Ranvier 1889), 
scientists have used this phenenomon to investigate its ability to regulate the two primary 
functions of the marrow, blood cell formation and bone turnover.  It has recently been 
shown that increases in marrow adipose have the ability to decrease hematopoiesis 
(Naveiras, Nardi et al. 2009).  In addition to the reported effects on blood cell formation, 
there is preliminary evidence to support that adipose tissue in the bone marrow may be a 
negative regulator of bone formation.  For example, adipocytes co-cultured with 
osteoblasts or conditioned medium from marrow adipocytes can inhibit osteoblast 
proliferation and block alkaline phosphatase production in vitro (Benayahu, Zipori et al. 
1993; Maurin, Chavassieux et al. 2000).  Histopathological studies have demonstrated 
decreased osteoblast activity and osteoclast numbers in sites of high marrow fat such as 
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caudal vertebrae, distal tibia, proximal ulna, and distal radius when compared to sites of 
low marrow fat such as lumbar vertebrae, proximal tibia, proximal humerus, and pelvis 
(Wronski, Smith et al. 1981; Li, Shen et al. 1996).  This is further supported by studies 
which demonstrate enhancement of trabecular bone formation after irradiation with 
suppression of marrow fat accumulation by a small molecule inhibitor of peroxisome 
proliferator-activated receptor-γ (PPAR-γ), a transcription factor required for adipocyte 
differentiation (Naveiras, Nardi et al. 2009).  Despite initial evidence, the precise 
mechanism for adipose regulation of bone metabolism and the role of secreted 
adipocytokines such as leptin is currently unknown.  
 
1.2 Leptin  
Function of Leptin 
The discovery of leptin, a secreted 16 kDa alpha-helical adipocytokine, began in 1949 
with the appearance of a spontaneous mutation in a non-inbred strain of mice at The 
Jackson Laboratory which produced offspring with severe obesity and sterility (Ingalls, 
Dickie et al. 1950).  These studies were extended with a novel mutation in C57BL/Ks 
inbred stock in 1966 which resulted in severe metabolic disturbances resembling human 
diabetes mellitus and many similarities to the original mutant (Hummel, Dickie et al. 
1966).   These mutants were termed obese ‘ob’ and diabetes ‘db’, respectively.  In 1978, 
following transfer of these mutants to a common inbred strain of mice, parabiosis 
experiments were performed which paired the circulation the mutant mice with one 
another as well as healthy donors (Coleman 1978).  Pairing of db/db mice with control or 
ob/ob animals resulted in starvation and death, implying that a circulating factor 
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produced by db/db animals was severely restricting food intake of the paired mice 
(Coleman 1978).  In contrast, pairing of ob/ob with control animals slowed weight gain 
and reduced food intake of the ob/ob mice suggesting that the control partner was 
producing a circulating factor responsible for regulation of satiety (Coleman 1978).  In 
sum, these findings implied that the ob/ob mouse was unable to produce sufficient satiety 
factor to limit food intake while the db/db mouse produced the factor, but could not 
respond to it (Coleman 1978).  Finally, forty-five years after the discovery of the obese 
mouse mutation, this circulating satiety factor was cloned and named leptin, derived from 
the greek ‘leptos’ meaning ‘thin’ (Zhang, Proenca et al. 1994).  Leptin has structural 
similarities to IL-6, IL-12, IL-15, and G-CSF and is produced primarily by the adipocyte 
(Laharrague, Larrouy et al. 1998; La Cava and Matarese 2004).  Leptin is recognized for 
its striking ability to regulate body mass and food intake.  Human leptin deficiency, 
though rare, results in prominent obesity and hypogonadism (Ozata, Ozdemir et al. 1999).  
Additional findings in the human population include death during childhood due to 
infection, alterations in hormone function, and decreased bone mineral density in some 
individuals (Ozata, Ozdemir et al. 1999).   
 
Serum leptin levels are strongly correlated to percent body fat and range from 
approximately 1 to 100ng/mL with an average of 8ng/mL in healthy controls and 
31ng/mL in obese subjects (Considine, Sinha et al. 1996).  Leptin signals through the 
hypothalamus and regulates food intake by producing a feeling of satiety after eating 
(Halaas, Gajiwala et al. 1995).  There were high hopes for leptin as a weight loss drug 
and in 1994 Rockefeller University licensed the human protein to Amgen, Inc. for twenty 
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million dollars (Gura 1999).  Subsequent human clinical trials were unfortunately 
disappointing with significant weight loss in only some of the human subjects and at only 
the highest doses tested (Heymsfield, Greenberg et al. 1999).  These findings made it 
clear that obesity is not a result of insufficient leptin, but rather the inability of the body 
to respond to the hormone.  Leptin resistance has since been demonstrated in control 
mice fed a high-fat diet (Lin, Thomas et al. 2000) and studies in rats have shown that 
obese animals require two to ten times more intracerebroventricular (ICV) leptin than 
controls for weight reduction (Cusin, Rohner-Jeanrenaud et al. 1996).  We do not yet 
know if there is differential potential for leptin resistance to develop in central vs 
peripheral sites.  Though leptin is not a generalized treatment for obesity due to central 
resistance, if peripheral resistance is less common leptin may be useful to treat peripheral 
imbalances including issues related to bone metabolism.    
 
Leptin Signaling 
Depending on its function, leptin has been classified as both a central neuroendocrine 
hormone and a peripherally acting cytokine.  The leptin receptor exists in multiple 
isoforms which are splice variants of the originally identified leptin receptor gene 
(Tartaglia, Dembski et al. 1995).  Only one of the isoforms retains the full signaling-
competent cytoplasmic domain and is referred to as the long-form leptin receptor or 
ObRb (Lee, Proenca et al. 1996).  The ObRa, ObRc, and ObRd isoforms are also 
membrane bound with an identical N-terminal segment to ObRb.  They are highly 
expressed in most tissues and lack the concentrated expression pattern that ObRb 
demonstrates in the hypothalamus (Tartaglia, Dembski et al. 1995).  The ObRe isoform, 
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termed the soluble of circulating leptin receptor, retains only the most proximal N-
terminal leptin-binding segment (Lee, Proenca et al. 1996).  The soluble receptor is 
highly expressed during early childhood and can reduce clearance of circulating leptin 
while both increasing its available pool or sequestering and inhibiting its actions 
depending on amount of molar excess ObRe available (Zastrow, Seidel et al. 2003). 
 
The signaling form leptin receptor, ObRb, has several identified signaling moieties that 
include a Jak2 domain and two phosphotyrosines 985 and 1138 (Banks, Davis et al. 
2000) (Figure 3).  Activation of the receptor results in recruitment and activation of Jak2 
which then phosphorylates and activates the cytoplasmic signaling phosphotyrosines.  
This conglomerate of signaling residues can then propagate signals through Stat3, SHP-2, 
mitogen-activated protein kinase (MAPK), phosphatidylinositol 3 kinase (PI3K), and 
AMP-activated protein kinase (AMPK) (Myers 2004) (Figure 3).  Stat3 signaling is 
induced through phosphotyrosine 1138 and gene targeted mutation of this residue results 
in mice with hyperphagia and obesity (Banks, Davis et al. 2000; Bates, Stearns et al. 
2003).  Induction of P-Stat3 through Tyr1138 leads to mRNA transcription of suppressor 
of leptin signaling, SOCS3 (suppressor of cytokine signaling-3) (Bjorbaek, Elmquist et 
al. 1998).  SOCS3, through its SH2 domain, can bind phosphorylated ObRb Tyr985 and 
Jak2 to inhibit Jak2 activity and block ObRb function (Banks, Davis et al. 2000).  
Accumulation of inhibitory SOCS3 has been implicated as a likely mechanism of leptin 
resistance and haplo-insufficiency for SOCS3 in mice protects against diet-induced 
obesity (Howard, Cave et al. 2004).     
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Figure 3.  Leptin signaling diagram.  Binding of leptin to its long-form receptor ObRb mediates signaling 
through receptor-based Jak2 and two signaling phosphotyrosines, Tyr985 (pY985) and Tyr1138 (pY1138).  
Jak2 can induce signals through insulin receptor substrate (IRS) proteins and extracellular signal related 
kinase (ERK).  Phosphorylation of Tyr985 allows interaction with SH2-containing phosphatase 2 (SHP-2) 
and further signal perpetuation via growth receptor bound 2 (Grb-2).  Tyr1138 induces phosphorylation of 
signal transducer and activation of transcription 3 (Stat3) and subsequent induction of suppressor of 
cytokine signaling 3 (SOCS3).  SOCS3, through its SH2 domain, negatively interacts with Tyr985 to 
inhibit perpetuation of leptin-induced signals.  Credit: Adapted from (Myers 2004).   
 
 
Similar to the ability of SOCS3 to bind ObRb Tyr985 through its SH2 domain, SH2-
containing phosphatase 2 (SHP-2) can also inhibit Tyr1138-mediated Stat3 activation 
while simultaneously activating MAP kinase (Banks, Davis et al. 2000).  This can then 
activate extracellular signal-related kinase (Erk) and c-Fos (Morikawa, Ueyama et al. 
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2004).  Phosphorylation of SHP-2 can also recruit growth receptor bound 2 (Grb-2) and 
link to small GTPases such as Ras and Raf (Zhang, Chen et al. 2005).  Gene targeted 
mutation of Tyr985 dampens the ability of ObRb to receive auto-inhibitory negative 
feedback through SOCS3 and SHP-2 and results in lean female mice that have decreased 
feeding, increased leptin sensitivity and are protected from high-fat diet-induced obesity 
(Bjornholm, Munzberg et al. 2007).   
 
The ability of ObRb to induce PI3K through Jak2-mediated phosphorylation of insulin-
receptor substrate (IRS) and Grb-2 proteins links leptin and insulin signaling.  Linkage of 
these pathways is implied by the fact that response to both leptin and insulin is impaired 
in most states of obesity.  In mice, deficiency of IRS2 results in hyperphagia and obesity 
and PI3K inhibitors can inhibit the anorectic actions of leptin in rats further supporting 
the crosstalk of leptin and insulin signaling (Burks, Font de Mora et al. 2000; Niswender, 
Morton et al. 2001).   
 
To summarize, ObRb signaling centrally through Stat3 via Tyr1138 has been shown to be 
responsible for mediating hyperphagia and obesity while Tyr985 is linked to auto-
inhibitory negative feedback and is likely responsible for central leptin resistance.  The 
function of these pathways exclusively in the hypothalamus fails to explain why targeted 
inhibition of ObRb in adipose tissue can result in peripheral fat accumulation (Huan, Li et 
al. 2003).  This may be explained by direct leptin regulation of peripheral lipid 
metabolism through AMPK.  AMPK activity is regulated by intracellular energy stores 
and can control fatty acid oxidation to generate ATP (Hardie and Carling 1997).  Leptin 
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can stimulate AMPK phosphorylation in skeletal muscle both directly and centrally 
through the sympathetic nervous system to activate fatty acid oxidation (Minokoshi, Kim 
et al. 2002).  There is also evidence that leptin inhibits differentiation of mesenchymal 
precursor cells to adipocytes in vitro, though the mechanism remains unknown (Thomas, 
Gori et al. 1999; Rhee, Sung et al. 2008; Scheller, Song et al. 2010).  This action has also 
been observed in vivo as long-term 28-day treatment of type I diabetic mice inhibited 
accumulation of adipose in the bone marrow (Motyl and McCabe 2009).       
    
Leptin regulation of bone formation 
Given the rarity of complete leptin deficiency in the human population, the effects of 
leptin on bone formation have been derived mainly in the context of rodent models.  In 
agreement with the decreased bone mineral density (BMD) observed in some leptin-
deficient humans (Ozata, Ozdemir et al. 1999), many studies of leptin-replete humans 
have shown a positive correlation between serum leptin and BMD.  The correlation 
between serum leptin and BMD has been published in over twenty-five reports 
containing information from over 10,000 patients (Table 1, 2).  Even with the significant 
focus on this area of research, the data have yet to reveal a clear picture of leptin 
regulation of bone mass in humans.  Interestingly, a dual pattern between males and 
females has emerged.  Of the twelve studies on 5,659 male patients, six found a negative 
correlation between leptin and bone mass while only two found positive (Table 1) (Sato, 
Takeda et al. 2001; Thomas, Burguera et al. 2001; Yoneda, Maruyama et al. 2001; Ruhl 
and Everhart 2002; Morberg, Tetens et al. 2003; Roemmich, Clark et al. 2003; Sun, Jing 
et al. 2003; Zoico, Zamboni et al. 2003; Dennison, Syddall et al. 2004; 
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Chanprasertyothin, Piaseu et al. 2005; Lorentzon, Landin et al. 2006; Weiss, Barrett-
Connor et al. 2006).  Looking specifically at patient numbers, this equates to 80% of the 
male participants enrolled in a study with a negative correlation while only 2% were 
enrolled in one with positive correlation.  Conversely, of the nineteen female studies, nine 
found a positive correlation (34% of study participants) while only two found negative 
correlation (4% of participants) (Table 2) (Ibanez, Potau et al. 2000; Martini, Valenti et 
al. 2001; Pasco, Henry et al. 2001; Thomas, Burguera et al. 2001; Yamauchi, Sugimoto et 
al. 2001; Yoneda, Maruyama et al. 2001; Ruhl and Everhart 2002; Roemmich, Clark et 
al. 2003; Roux, Arabi et al. 2003; Sahin, Polat et al. 2003; Ushiroyama, Ikeda et al. 2003; 
Zoico, Zamboni et al. 2003; Dennison, Syddall et al. 2004; Huang, Cheng et al. 2004; 
Chanprasertyothin, Piaseu et al. 2005; Yilmazi, Keles et al. 2005; Zhong, Wu et al. 2005; 
Weiss, Barrett-Connor et al. 2006; Oguz, Tapisiz et al. 2009).  The percent of positive 
participants in the females may be deflated due to the large number of patients in one 
study (49% of total females) which found no correlation between leptin and bone mass 
(Ruhl and Everhart 2002).  This study is, however, limited because dual-energy x-ray 
absorptiometry (DXA) was performed only on the femur and not the lumbar vertebrae or 
whole body, which means that a site-specific correlation may have been missed.  
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Table 1.  Correlation of leptin and bone mineral density in males.  A summary of published manuscripts investigating the ability of circulating leptin 
concentration to correlate with bone mineral density.  Correlations reported are the final values from the study and most have been normalized to factors such as 
body mass index and age. 
Gender Age Number Method Reference Correlation 
Male 43-70 26 DXA - radius Yoneda 2001 Positive
Male 68-75 92 DXA - whole body, hip, femur Zoico 2003 Positive
Male Youth 9-17 28 DXA - whole body, femur, lumbar spine Reommich 2003 None
Male 60-75 170 DXA - lumbar spine, femur Dennison 2004 None
Male 45-92 498 DXA - hip, lumbar spine, radius Weiss 2006 None
Male 23-90 343 DXA - hip, lumbar spine, radius Thomas 2001 None
Male 21-73 221 SPA - right calcaneus (heel) Sato 2001 Negative
Male 20+ 2761 DXA - femur Ruhl 2002 Negative
Male 18-66 50 DXA - whole body Sun 2003 Negative
Male Avg 50 327 DXA - whole body Morberg 2003 Negative
Male 20-80 75 DXA - lumbar spine, femur Chanprasertyothin 2005 Negative
Male 18-20 1068 DXA - lumbar spine, femur, whole body Lorentzon 2006 Negative
1
2
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Gender Age Number Method Reference Correlation 
Female 34-93 165 DXA - hip, lumbar spine, radius Thomas 2001 Positive
Female 48-78 139 DXA - femur, lumbar spine, whole body Yamauchi 2001 Positive
Female 68-75 171 DXA - whole body, hip, femur Zoico 2003 Positive
Female 45-92 411 DXA - hip, lumbar spine, radius Weiss 2006 Positive
Female Avg 51 122 DXA - lumbar spine, femur Oguz 2009 Positive
Female 21-54 137 DXA - hip, lumbar spine, radius Thomas 2001 Positive
Female 20-80 676 DXA - lumbar spine, femur, whole body Zhong 2005 Positive
Female Youth 5-14 52 DXA - lumbar spine Ibanez 2000 Positive
Female 20-91 214 DXA - whole body, lumbar spine, femur Pasco 2001 Positive
Female 39-82 123 DXA - whole body Martini 2001 None
Female 43-68 25 DXA - radial bone Yoneda 2001 None
Female 55+ 1148 DXA - femur Ruhl 2002 None
Female 45-65 100 DXA - lumbar spine, femur Sahin 2003 None
Female Avg 54 121 DXA - hip, lumbar spine Roux 2003 None
Female 60-75 132 DXA - lumbar spine, femur Dennison 2004 None
Female 20-80 63 DXA - lumbar spine, femur Chanprasertyothin 2005 None
Female Avg 53 90 DXA - lumbar spine, femur Yilmazi 2005 None
Female 20-55 1906 DXA - femur Ruhl 2002 None
Female Youth 9-17 31 DXA - whole body, femur, lumbar spine Reommich 2003 None
Female Youth 10-19 105 DXA - whole body Huang 2004 None
Female 47-58 215 DXA - lumbar spine Ushiroyama 2003 Negative
Female 20-80 51 DXA - lumbar spine, femur Chanprasertyothin 2005 Negative  
Table 2.  Correlation of leptin and bone mineral density in females.  A summary of published manuscripts investigating the ability of circulating leptin 
concentration to correlate with bone mineral density.  Correlations reported are the final values from the study and most have been normalized to factors such as 
body mass index and age. 
 
 
1
3
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In leptin signaling deficient mice, two unique bone changes are observed with contrasting 
phenotypes in the limbs and spine (Hamrick, Pennington et al. 2004).  The leptin 
deficient mouse, known as ob/ob, contains a nonsense mutation in codon 105 of the 16 
kDa leptin transcript (Zhang, Proenca et al. 1994; MacDougald, Hwang et al. 1995).  The 
leptin protein, expressed predominantly in adipose tissue of normal mice, is missing from 
homozygous mutant mice.  The second model, known as db/db, is a leptin-receptor 
mutant mouse with a spontaneous autosomal recessive mutation that was discovered at 
The Jackson Laboratory, Bar Harbor, ME in 1966 (Hummel, Dickie et al. 1966).  A G-to-
T transversion in this allele created a donor splice site that causes abnormal splicing and a 
106 nucleotide insertion in the transcript, leading to premature termination of the 
cytoplasmic domain of the long-form leptin receptor (ObRb) and loss of its signal 
transducing function (Lee, Proenca et al. 1996).  Both mutant mice display a phenotype 
of uncontrolled eating and rapid weight gain.  They also exhibit hyperphagia, glucose 
intolerance, elevated plasma insulin, subfertility, and impaired wound healing (Charlton 
1984).  Interestingly, leptin-deficient mice have significantly shorter femora, lower 
femoral bone mineral content (BMC), BMD, cortical thickness, and trabecular bone 
volume when compared to lean mice (Kawashima and Castro 1981; Steppan, Crawford et 
al. 2000; Hamrick, Pennington et al. 2004).  However, these same mice have significantly 
increased vertebral length, lumbar BMC, lumbar BMD, and trabecular bone volume 
when compared to lean controls (Hamrick, Pennington et al. 2004) (Figure 4, Figure 5). 
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Figure 4. Leptin-deficient ob/ob mice have increased lumbar vertebral trabecular bone parameters. (A) L2 
vertebrae were imaged with microCT and a core sample taken through the vertebral body, excluding the 
cortical bone, for analysis.  (B,C) Trabecular bone volume fraction (%) and bone mineral density (mg/cc) 
were significantly higher in ob/ob mice when compared to controls.  N=8 vertebrae.  WT: wild type.  
Credit: E.L Scheller, unpublished data. 
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Figure 5. Leptin-deficient ob/ob mice have decreased distal femoral trabecular bone parameters. (A) 
Femurs were imaged with microCT and a sample taken at the distal femur, excluding the cortical bone and 
primary spongiosa, for analysis.  (B,C) Trabecular bone volume fraction (%) and bone mineral density 
(mg/cc) were significantly lower in ob/ob mice when compared to controls.  N=5 femurs.  WT: wild type.  
Credit: E.L Scheller, unpublished data. 
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The phenotypic differences between the vertebral and long bone compartments of leptin 
transgenic mice have not yet been explained.  In vivo studies have highlighted the 
importance of leptin administration modes and bone type analysis in determining the 
effects of leptin on bone mass.  For example, intracerebroventricular (ICV) infusion of 
8ng/hr leptin with subsequent analysis of vertebrae bone mass in 4 to 6 month old mice 
shows a 15 to 50% decrease in trabecular volume after twenty-eight days (Ducy, Amling 
et al. 2000; Takeda, Elefteriou et al. 2002).  However, subcutaneous delivery of 10µg/day 
leptin in 15 week old leptin-deficient ob/ob mice for fourteen days results in greater than 
30% increase in fluorochrome-labeled tibial endosteal surface (Steppan, Crawford et al. 
2000; Hamrick, Della-Fera et al. 2005).  Similarly, IP injection of 50µg/day leptin to 4 
wk old ob/ob mice for 21 days produces a 6% increase in femoral length and an 84.2% 
increase in distal femoral trabecular mineral content when compared to controls (Steppan, 
Crawford et al. 2000).  It is important to note that studies evaluating bone loss after leptin 
administration focus on the vertebrae while those focused on bone gain use long bone 
models.  This dichotomy highlights the need for further investigation to definitively 
define the role of leptin in regulation of peripheral bone metabolism. 
 
There are a few important points to consider when analyzing differences in the current 
literature.  First, physiologic concentrations of circulating leptin average 8ng/mL in both 
mouse and human and rarely exceed 40ng/mL, even in states of high leptin production 
such as obesity (Hassink, Sheslow et al. 1996; Ahren, Mansson et al. 1997).  It is possible 
that local levels of leptin adjacent to adipocytes in the bone marrow can significantly 
exceed this threshold.  However, when considering serum concentrations only, in all but 
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one study highlighted above, stimulation was performed with leptin concentrations far 
exceeding physiologic levels.  Second, the reported circulating half-life of recombinant 
leptin is only thirty minutes to three hours (Chehab 1997).  Thus, continuous 
administration vs bolus injection could make a large difference in the actual circulating 
leptin concentration.  Finally, leptin is a known mitogen that has even been classified as a 
growth factor in some circumstances (Hu, Juneja et al. 2002).  Thus, administration of 
leptin to immature four week old mice may promote expansion of the growth plate 
through a mechanism entirely different than that required for later regulation of adult 
bone remodeling.  A thorough understanding of these limitations is necessary to design 
experiments that directly relate to physiologic regulation of post-developmental bone 
mass.    
 
Ability of leptin to regulate peripheral cells 
Two possible mechanisms of leptin regulation of bone formation have been described.  
ICV leptin injection can increase sympathetic nerve activity when binding to its cognate 
receptors in the hypothalamus (Dunbar, Hu et al. 1997).  This central regulation of 
sympathetic neural output can then alter osteoblast and osteoclast function and result in 
decreased bone mass (Ducy, Amling et al. 2000).  The ability of leptin to directly regulate 
peripheral cells without a hypothalamic intermediate has been debated, but has become 
increasingly accepted as the presence of the signaling-competent leptin receptor (ObRb) 
has been reported on many cell types including mesenchymal stem cells, osteoblasts, 
skeletal muscle, adrenal glands, kidney, adipocytes, immune cells, liver, and pancreatic 
beta-cells (Emilsson, Liu et al. 1997; Hoggard, Mercer et al. 1997; Lollmann, Gruninger 
 19 
et al. 1997; Kielar, Clark et al. 1998; Lord, Matarese et al. 1998; Thomas, Gori et al. 
1999; Hess, Pino et al. 2005).  Immunohistochemical staining for green fluorescent 
protein (GFP) of femurs from mice with enhanced-GFP (EGFP) linked to ObRb 
expression (Leinninger, Jo et al. 2009) reveals putative ObRb expressing cells including 
adipocytes, lymphocytes, and some bone lining cells (Figure 6, Figure 7).     
 
 
Control
ObRb-EGFP
Counterstain Chicken Anti-GFP Inverted Image
 
Figure 6. Immunohistochemistry for GFP of mice with ObRb-linked EGFP expression compared to control 
GFP negative mice.  Left-most panel displays hematoxilyn counterstain image.  Presence of GFP was 
determined with chicken anti-GFP primary antibody, followed by goat-anti chicken Cy3 secondary 
antibody.  Center image reveals Cy3 positive areas.  To aid in visualization, images were inverted and 
changed to black and white in Adobe Photoshop CS3 (right-most panel).  Arrows highlight lymphocytes 
within the marrow.  10x magnification.  EGFP: enhanced green fluorescent protein.  GFP: green 
fluorescent protein.  Credit: E.L Scheller, unpublished data. 
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Figure 7. GFP immunohistochemistry of mice with ObRb-linked EGFP expression reveals suspected 
ObRb expressing cells in vivo.  Image prepared as detailed in previous figure.  Red arrows: adipocytes; 
Green arrow: lymphocyte; Blue arrow: bone lining cells; Yellow arrow: unknown positive cells; B: bone.  
Credit: E.L Scheller, unpublished data. 
The physiologic relevance of peripheral leptin modulation of bone formation is currently 
unknown but preliminary in vitro evidence suggests that leptin has the ability to regulate 
bone forming cells such as the bone marrow stromal cell (BMSC) and the osteoblast.  
Leptin can enhance differentiation of human clonal BMSCs (hMS2-12) to osteoblasts as 
shown by increases in mineralization, alkaline phosphatase, and osteocalcin while 
inhibiting differentiation toward adipocytes (Thomas, Gori et al. 1999).  Similarly, 
recombinant leptin stimulation of human primary BMSCs in vitro has been shown to 
promote osteogenic differentiation and partly inhibit adipogenic differentiation at 0.6 and 
1.5µg/mL concentrations (Chang, Shih et al. 2006).  Treatment of human iliac crest 
osteoblasts with lower concentrations of 100ng/mL leptin initially inhibited 
mineralization after two weeks in vitro, however, continued culture for 4-5 weeks 
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enhanced calcified nodule production (Reseland, Syversen et al. 2001; Gordeladze, 
Drevon et al. 2002).  It has even been suggested that leptin is produced by primary human 
osteoblasts directly, though expression was not found in commercially available cells 
(Reseland, Syversen et al. 2001).  However, unlike with human cells, similar studies with 
primary BMSCs isolated from C57BL/6J mice have failed to demonstrate any effects 
with 1.2µg/mL leptin stimulation of established cultures for 21 days (Ducy, Amling et al. 
2000).  We found similar negative results with BMSCs from control, ob/ob, and db/db 
mice after treatment with 100ng/mL leptin for fourteen days (Scheller, Song et al. 2010).       
 
Though this dissertation will focus mainly on the ability of leptin to regulate 
mesenchymal lineages and macrophages, it should be noted that leptin may also be able 
to influence osteoclast activity.  The nature of this influence is currently inconclusive.  
Histologically, ob/ob and db/db mice have a two-fold increase in osteoclast number when 
compared to controls (Ducy, Amling et al. 2000).  However, the excretion of urinary 
deoxypyridinoline crosslink, a biochemical marker of bone resorption, was not impaired 
in these animals (Ducy, Amling et al. 2000).  Conversely, leptin deficient rats have 
increased osteoclast surface, but no increase in numbers (Tamasi, Arey et al. 2003).  
Isolation of primary bone marrow osteoclast progenitors from leptin-deficient mice 
shows no deficiency in osteoclast differentiation or in their ability to form resorption 
lacunae on dentin (Ducy, Amling et al. 2000).  Other in vitro studies show that leptin 
partially inhibits osteoclastogenesis at 10
-11
M in primary mouse marrow cultures but does 
not affect bone resorption of mature osteoclasts (Cornish, Callon et al. 2002).  The 
scattered nature of the current published data are inconclusive as to the effects of leptin 
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on osteoclast formation and activity.  However, this may be linked to leptin actions on the 
macrophage population since they share a common myeloid progenitor. 
 
Monocytes and macrophages are produced in the bone marrow from hematopoietic stem 
cells and enter and exit this site through the vasculature.  While the macrophage has long 
been appreciated as a key component of the immune system, an essential role for 
macrophages in bone homeostasis was only recently confirmed when induced depletion 
of macrophages in a mouse model ablated the mature osteoblast bone-forming surface 
(Chang, Raggatt et al. 2008).  In addition to regulation of osteogenesis, macrophage-
released cytokines are regulators of fibroblast and endothelial cell proliferation and 
studies have speculated that reduced macrophage infiltration may, in part, be responsible 
for increased rates of healing of oral mucosa compared to dermal sites (Szpaderska, 
Zuckerman et al. 2003).  Macrophages are acutely sensitive to changes in their 
surrounding microenvironment and can respond to in vitro leptin concentrations as low as 
1ng/mL, well under physiologic range (Maingrette and Renier 2003).  Leptin is a potent 
monocyte/macrophage chemoattractant (Gruen, Hao et al. 2007) and plays a significant 
role in the regulation of pro-inflammatory immune responses (Loffreda, Yang et al. 1998; 
La Cava and Matarese 2004).  Of note, leptin binding to macrophages has been shown to 
enhance secretion of the pro-inflammatory cytokines TNF-α, IL-6, and IL-12 (Gainsford, 
Willson et al. 1996; Santos-Alvarez, Goberna et al. 1999; Zhao, Hou et al. 2005).  Many 
studies have highlighted the ability of monocytes and macrophages to interact with 
BMSCs and BMSCs have been implicated as negative regulators of monocyte 
differentiation (Jiang, Zhang et al. 2005).  Furthermore, it has been demonstrated that the 
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macrophage can provide signals such as bone morphogenetic protein 2 (BMP-2) and 
TGF-β to promote osseous wound healing (Champagne, Takebe et al. 2002).  
Conversely, the absence of monocytes and macrophages as observed in the M-CSF 
deficient op/op mouse results in an osteopetrotic bone phenotype due to impaired 
osteoclastogenesis (Abboud, Woodruff et al. 2002).  Since the macrophage can readily 
respond to sub-physiologic leptin levels with changes in cytokine production and 
migration, we hypothesized that regulation of macrophage activity by leptin may 
facilitate its actions as an osteoimmunologic intermediate and contribute to bone 
formation and metabolism.     
 
1.3 Clinical Challenges  
Osteoimmunology is defined as the interplay between the immune system and bone 
metabolism.  This field was generated from the realization that during times of 
inflammation and stress, immune cells generated in the bone secrete factors that can 
profoundly affect bone regulation.  For example, TNF-α and IL-4 can inhibit the 
differentiation of osteoblasts (Lewis, Liggitt et al. 1993; Gilbert, He et al. 2000; Ura, 
Morimoto et al. 2000).  Conversely, conditioned media from inflammatory T cells can 
rapidly induce the differentiation of BMSCs to mature osteoblasts (Rifas, Arackal et al. 
2003).  This circle of creation and influence in the marrow cavity has important 
implications for the study of inflammation-linked bone disorders including osteoporosis, 
cancer metastasis to the bone, arthritis, osteomyelitis, periodontal disease, and 
osteonecrosis of the jaw.  In addition to the contribution of osteoimmunology to bone 
disorders, it also plays a significant role in our ability to regenerate lost osseous tissues in 
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the presence of infection and inflammation.  Understanding the ability of endogenous 
cytokines such as leptin to regulate bone formation directly or through an immunologic 
intermediate such as the macrophage will contribute to our ability to both regenerate 
tissues and to treat disease.   
 
1.4 Summary 
Accumulation of peripheral adipose tissue has significant consequences including 
increased risk for vascular disease, type 2 diabetes, cancer (endometrial, breast, and 
colon), high blood pressure, stroke, liver and gallbladder disease, sleep apnea, 
osteoarthritis, and even bisphosphonate-induced ONJ (CDC 1998; Wessel, Dodson et al. 
2008).  Peripheral adiposity or body mass index (BMI) has also been repeatedly linked to 
changes in bone mass.  Despite recognition that, like the body, the bone marrow can also 
vary widely in degree of adiposity, we do not yet understand the ramifications of this 
tightly controlled presence of adipocytes.  For example, osteoporosis has been linked to a 
dense infiltration of marrow by adipocytes (Burkhardt, Kettner et al. 1987).  However, it 
is unclear if this infiltration is causal to the disease or rather an attempted protective 
response by the body.     
 
Leptin is a potent adipocyte secretory product that can act both in a central 
neuroendocrine and a peripheral cytokine-like manner to regulate bone mass.  The ability 
of leptin to act peripherally is controversial but is supported by positive associations 
between circulating leptin and BMD observed in human studies that can not be explained 
by negative central regulation (Table 1,Table 2).  The majority of current research has 
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focused on the ability of leptin to regulate osteoblast function and mesenchymal stem cell 
differentiation in vitro.  These studies have used concentrations of leptin well above 
physiologic norms and have failed to address the physiologic relevance of leptin actions 
on these cells.  In addition, though leptin has been purported as a potent regulator of 
macrophage pro-inflammatory cytokine production, this ability has never been studied in 
the context of bone metabolism.  In this body of work we will examine the physiologic 
relevance of leptin actions on bone formation through a macrophage osteoimmunologic 
intermediate, the osteoblast, and the mesenchymal precursor cell (Figure 8).  We will also 
explore the relevance of these findings to a pathologic condition, osteonecrosis of the 
jaw. 
Macrophage
Adipocyte
Osteoblast
Mesenchymal
Precursor
Leptin
2
1
3
 
Figure 8.  Summary of research direction.  This dissertation will investigate the physiologic ability of 
leptin, an adipocytokine, to regulate bone formation though (1) a macrophage osteoimmunologic 
intermediate, (2) the osteoblast, and (3) the mesenchymal precursor cell.   
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CHAPTER 2 
A ROLE FOR THE MYELOID LINEAGE IN LEPTIN-REGULATED BONE 
METABOLISM  
2.1 Summary 
 
Leptin influences bone formation centrally through the hypothalamus or peripherally by 
acting on osteoblasts or their precursors.  However, neither mechanism explains the 
divergent, gender-specific correlation between leptin and bone mineral density in 
humans.  Although leptin is a potent regulator of pro-inflammatory immune responses, a 
potential role for leptin as an osteoimmunologic intermediate in bone metabolism has not 
been tested.  Mice with myeloid-specific ablation of the long-form leptin receptor (ObRb) 
were generated using mice expressing cre-recombinase from the lysoszyme M promoter.  
At 12 weeks of age the conditional knockout mice did not display any appreciable 
phenotype.  However, at 52 weeks two changes were noted.  First, there was a mild 
increase in liver inflammation.  Second, a gender-specific, divergent bone phenotype was 
observed.  Female mice displayed a consistent trend toward decreased trabecular bone 
parameters including reductions in bone volume fraction, trabecular number, and bone 
mineral content.  Conversely, male mice lacked trabecular changes, but had statistically 
significant increases in cortical bone volume, thickness, and bone mineral density with 
equivalent total cortical volume.  Since the year 2000, over twenty-five studies on more 
than 10,000 patients have attempted to determine the correlation between leptin and bone 
mineral density.  The results have revealed a gender-specific correlation between leptin 
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and bone mineral density similar to that observed in our LysM transgenic animals.  We 
hypothesize and show initial evidence that regulation of myeloid lineage cells such as 
macrophages by leptin may facilitate their actions as an osteoimmunologic intermediate 
and contribute to leptin-regulated bone formation and metabolism. 
 
2.2 Introduction 
Leptin, a pro-inflammatory cytokine synthesized primarily by adipocytes, is a 
neuroendocrine regulator of appetite (Pelleymounter, Cullen et al. 1995), energy 
metabolism (Breslow, Min-Lee et al. 1999), immune function (La Cava and Matarese 
2004), and bone mass (Ducy, Amling et al. 2000; Scheller, Song et al. 2010).  Leptin is 
also a potent monocyte/macrophage chemoattractant (Gruen, Hao et al. 2007) and plays a 
role in the regulation of pro-inflammatory immune responses (Loffreda, Yang et al. 1998; 
La Cava and Matarese 2004).  Leptin binding to macrophages enhances secretion of the 
pro-inflammatory cytokines TNF-α, IL-6, and IL-12 (Gainsford, Willson et al. 1996; 
Santos-Alvarez, Goberna et al. 1999; Zhao, Hou et al. 2005).  Macrophages are acutely 
sensitive to changes in their surrounding microenvironment and respond to leptin 
concentrations as low as 1ng/mL in vitro (Maingrette and Renier 2003).  Though there 
are many studies that correlate obesity with increases in systemic inflammation and 
circulating leptin (Considine, Sinha et al. 1996), the physiologic significance of leptin 
interactions with the myeloid lineage has not yet been determined.  
 
Over twenty-five studies on more than 10,000 patients have attempted to determine the 
relationship between circulating leptin and bone mineral density (BMD) in humans.  The 
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sum of the results, though varied, has revealed divergent patterns between males and 
females.  While leptin often correlates positively with BMD in females, the opposite is 
noted in males (Table 1,Table 2) (Thomas, Burguera et al. 2001; Ruhl and Everhart 2002; 
Zhong, Wu et al. 2005; Lorentzon, Landin et al. 2006).  Despite extensive analysis, the 
mechanism of peripheral leptin regulation of bone mass is not entirely understood.  
Though it is accepted that leptin may act through a central neuroendocrine relay to 
negatively modulate bone metabolism (Ducy, Amling et al. 2000), the appearance of 
leptin resistance with age or obesity may impair these effects.  Alternatively, leptin may 
act directly on osteoblasts.  However, studies that examine this activity in vitro 
consistently use leptin concentrations far exceeding physiologic norms and mice 
conditionally lacking osteoblastic ObRb fail to demonstrate a bone phenotype (Thomas, 
Gori et al. 1999; Chang, Shih et al. 2006; Shi, Yadav et al. 2008; Scheller, Song et al. 
2010).  Lastly, it has been shown that leptin may negatively regulate mesenchymal 
precursor cell differentiation to influence bone length and BMD (Scheller, Song et al. 
2010).  However, this would likely contribute more to bone formation during growth and 
healing and not general bone turnover.  We lack an experimental model that can mimic 
the modest, divergent, gender-specific changes in BMD that have been noted in adult 
humans.  Since the macrophage can readily respond to subphysiologic leptin levels with 
changes in cytokine production and migration, we hypothesize that regulation of 
macrophage activity by leptin may facilitate its actions as an osteoimmunologic 
intermediate and contribute to bone formation and metabolism.  To test this hypothesis, 
we generated a conditional myeloid lineage leptin-receptor (ObRb) deficient mouse.   
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2.3 Materials and Methods 
 
Conditionally Regulated ObRb Mice 
All procedures were approved by the University Committee on the Use and Care of 
Animals.  LysM-Cre mice were obtained from Jackson Laboratory (Bar Harbor, Maine, 
USA Cat:004781) (Clausen, Burkhardt et al. 1999).  Flox/Flox Jak2-ObRb mice were 
obtained from Dr. Martin Myers (University of Michigan) with permission of Dr. 
Streamson Chua (Columbia University) (McMinn, Liu et al. 2004).  To generate LysM-
Cre crossed with ObRb floxed/floxed (
F/F
) mice, one LysM
Cre+F/-
 male was bred with two 
LysM
Cre-F/F
 females and pups were genotyped via PCR analysis of tail biopsy DNA as 
reported previously (McMinn, Liu et al. 2004).  Analysis was performed on LysM
Cre-
, 
LysM
Cre+F/-
 and LysM
Cre+F/F
 littermates.  Recombination and deletion of the loxP flanked 
allele was determined using the three-primer system designed by McMinn et al (McMinn, 
Liu et al. 2004).   
 
MicroCT 
Femurs were scanned in a vivaCT 40 µCT system (Scanco Medical, Switzerland) with an 
isotropic voxel size of 10.5µm (55 kVp, 145µA, 1000 projections per 180 degrees, 200 
ms integration time) as described previously (Scheller, Song et al. 2010). Briefly, 2D 
transverse slices were reconstructed into 2048x2048 pixel matrices. Cortical bone 
parameters were measured by analyzing 50 slices (0.525mm) of the mid-diaphysis. 
Trabecular bone parameters were measured by analyzing 101 slices (1.06mm) of the 
distal metaphysis 0.105 mm proximal to the primary spongiosa in the marrow cavity to 
assure that only trabecular bone was analyzed. For both analyses, a Gaussian low-pass 
 30 
filter was used (σ=0.8, support=1).  Analysis groups: 12 week female LysM
Cre-
 (N=6), 
LysM
Cre+F/F
 (N=6); 52 week female LysM
Cre-
 (N=7), LysM
Cre+F/F
 (N=4); 52 week male 
LysM
Cre-
 (N=6), LysM
Cre+F/F
 (N=6).  One of the male 52 week old LysM
Cre+F/F
 samples 
was eliminated as an outlier because values were greater than two standard deviations 
from the mean. 
 
Statistics  
A two-tailed, homoscedastic t test was used to calculate differences between control and 
experimental groups. Values are reported as the mean 
+
/- the standard deviation.  P<0.050 
was considered statistically significant.  P<0.150 was considered to represent a non-
significant trend.   
 
2.4 Results 
Generation of Myeloid lineage-specific leptin receptor knockout mice  
Mice with loxP sites flanking the ObRb Jak2 signaling component (McMinn, Liu et al. 
2004) were bred with mice expressing Cre recombinase under the control of the 
Lysozyme M  (LysM) promoter (Clausen, Burkhardt et al. 1999) to specifically eliminate 
ObRb function in myeloid lineage cells (LysM
Cre+F/F
).  DNA was isolated from tissues of 
12 week old LysM
Cre+F/F
 mice and used for PCR amplification to determine the extent of 
deletion of the floxed locus.  DNA was also harvested from macrophages differentiated 
from primary bone marrow with 50ng/mL M-CSF for two days.  Results revealed the 
highest level of deletion in cultured macrophages, whole bone marrow (WBM), tail, and 
spleen extracts (Figure 9).  Low-level recombination was observed in all other tissues 
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except for the hypothalamus (Figure 9).  Mice were phenotypically similar with 
exception of slight obesity observed in both the male heterozygote LysM
Cre+F/-
 (14% 
increase, p=0.007) and homozygote LysM
Cre+F/F
 (11% increase, p=0.062) mice at 50 
weeks (Data Not Shown).  No differences were noted in the mass of females from 3 to 52 
weeks of age (Figure 9).   
 
Because mice with complete ObRb knockout are known to have significant 
hepatomegaly (Menahan 1983), we quantified liver mass at necropsy.  At 52 weeks, the 
LysM
Cre+F/F
 female mice had an 11.3
+
/-0.9% reduction in liver mass/body mass ratio 
(P=0.016) when compared to the LysM
Cre-
 mice that was not present in the heterozygotes 
(Figure 10).  Histological analysis revealed moderate steatohepatitis with microscopic 
features including hepatocyte ballooning, finely divided fat droplets in the hepatocyte 
cytoplasm, intracytoplasmic accumulations of Mallory hyaline, and inflammatory 
infiltrates consisting predominately of neutropils with some lymphocytes (Figure 10).  
Histological features of steatohepatitis were present in both the 12 month old LysM
Cre-
 
and LysM
Cre+F/F
 mice, however, the presence of inflammatory islands of ten or more cells 
was significantly increased in the LysM
Cre+F/F
 mice (Figure 10).  No changes in spleen 
size were noted (Data Not Shown).      
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Figure 9. Generation of LysM
Cre+F/F
 Mice. LysM-Cre mice were mated with mice with loxP sites flanking 
exon 17 of the long-form leptin receptor (ObRb) to generate myeloid-specific ObRb knockout mice.  (A) 
Genomic DNA PCR of tissues from 12 week old animals or primary bone marrow macrophages cultured in 
vitro showing the intact (~646 base pairs) and deleted (~200 base pairs) bands, lanes cropped from the 
same gel.  (B) Representative photo, female, 3 months old.  (C) Body mass of transgenic female mice from 
3 to 52 weeks.  N=6-8.  WBM: Whole Bone Marrow.  Hypothal: hypothalamus.  Credit: E.L. Scheller, 
unpublished data.    
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Because complete ObRb KO mice have altered femoral bone parameters (Hamrick, 
Pennington et al. 2004), femurs were harvested from mice at 12 and 52 weeks of age and 
cortical and trabecular bone parameters were analyzed with microCT.  Statistically 
significant differences in bone parameters were not present at 12 weeks of age (Table 3) 
(Scheller, Song et al. 2010).  At 52 weeks, females demonstrated a trend toward 
decreased trabecular bone volume fraction (-31%, p=0.105), trabecular number (-18%, 
p=0.081), and bone mineral content (-31%, p=136) (Table 3).  This corresponded to an 
increase in trabecular spacing (+16%, p=0.129) (Table 3).  These trends were not present 
in the males, however, increases in cortical parameters were observed including bone 
volume (+9.3%, p=0.036), cortical bone fraction (+9.0%, p=0.089), cortical thickness 
(+10.5%, p=0.038), BMC (+13.7%, p=0.006), and BMD (+4.0%, p<0.001), but total 
volume was unchanged (Table 3).   
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Figure 10.  LysM
Cre+F/F
 liver phenotype.  (A) Liver histology.  (B) 52 week old female liver mass and liver 
mass/body mass ratio (N=6-8).  (C) Number of inflammatory islands per field (N=3 mice, 3 liver sections 
each, 10 fields/section).  Inset contains genomic DNA PCR to check for Cre-lox recombination.  Credit: 
E.L. Scheller, unpublished data.    
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Trabecular Control LysM+ p value Control LysM+ p value Control LysM+ p value
Bone Volume Fraction (%) 24+/-3.9 25+/-5.0 0.581 6.9+/-1.9 4.8+/-1.9 0.105 7.4+/-1.3 7.7+/-3.1 0.842
Tb. Number (1/mm) 5.96+/-0.54 5.79+/-0.67 0.625 2.19+/-0.35 1.80+/-0.23 0.081 2.35+/-0.27 2.48+/-0.62 0.642
Tb. Thickness (mm) 0.061+/-0.002 0.060+/-0.005 0.759 0.063+/-0.007 0.063+/-0.006 0.982 0.058+/-0.007 0.058+/-0.007 0.879
Tb. Spacing (mm) 0.175+/-0.016 0.183+/-0.022 0.488 0.487+/-0.082 0.566+/-0.060 0.129 0.442+/-0.059 0.440+/-0.114 0.970
BMC (mg HA) 463+/-74 452+/-105 0.837 142+/-46 98+/-36 0.136 176+/-46 184+/-78 0.843
Cortical Control LysM+ p value Control LysM+ p value Control LysM+ p value
Total Volume (mm^3) 0.86+/-0.04 0.84+/-0.05 0.379 1.08+/-0.09 1.06+/-0.07 0.787 1.18+/-0.08 1.19+/-0.09 0.902
Bone Volume (mm^3) 0.408+/-0.010 0.398+/-0.036 0.512 0.509+/-0.047 0.512+/-0.021 0.900 0.538+/-0.046 0.588+/-0.020 0.036
Cortical Bone Fraction (%) 47.5+/-2.0 47.5+/-2.7 0.978 47.2+/-3.0 48.2+/-2.3 0.581 45.5+/-4.0% 49.6+/-3.4 0.089
Cortical Thickness (mm^3) 0.201+/-0.006 0.199+/-0.015 0.769 0.222+/-0.016 0.225+/-0.007 0.684 0.219+/-0.020 0.242+/-0.013 0.038
BMC (mg HA) 480+/-14 472+/-46 0.682 627+/-64 638+/-33 0.758 656+/-57 746+/-25 0.006
BMD (mg HA/ccm) 1176+/-18 1186+/-34 0.561 1232+/-27 1236+/-29 0.778 1219+/-6 1268+/-17 <0.001
LysMCre+F/F % Change vs Cre- Control
12 wk Female 52 wk Female 52 wk Male
 
Table 3. Femoral microCT analysis of LysM transgenic mice.  No differences were noted in femoral cortical or trabecular parameters at 3 months of age.  At 12 
months, the LysM
Cre+F/F
 females showed a trend toward decreased bone volume fraction and trabecular number.  Conversely, the males had no noted changes in 
trabecular parameters, but had significant increases in cortical bone volume, bone mineral content (BMC) and bone mineral density (BMD).  Female LysM
Cre-
 
N=7, LysM
Cre+F/F
 N=4.  Male LysM
Cre-
 N=6, LysM
Cre+F/F
 N=6.  Credit: E.L. Scheller, unpublished data.     
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2.5 Discussion 
Osteoimmunology is an emerging field of research that views regulation of bone 
metabolism within the context of immune function.  While the macrophage has long been 
appreciated as a key component of the immune system, an essential role for macrophages 
in bone homeostasis was only recently confirmed when induced depletion of osteal tissue 
macrophages in a mouse model ablated the mature osteoblast bone-forming surface 
(Chang, Raggatt et al. 2008).  In addition to the bone changes, we report the liver 
phenotype of the 52 week old LysM
Cre+F/F
 animals as an interesting finding, though we do 
not yet understand its significance.  The slight increase in liver inflammation observed in 
the conditionally regulated mice may indicate that leptin actions on myeloid lineage cells 
could regulate homing to the liver.      
 
The trend toward decreased trabecular bone observed in the aged female but not the male 
LysM
Cre+F/F
 mice and the increase in cortical bone mass in the male but not the female 
closely mimics the association between leptin and BMD observed in humans.  For 
example, many studies cite a modest positive correlation between leptin and BMD in 
post-menopausal adult females (Thomas, Burguera et al. 2001; Zhong, Wu et al. 2005).  
Thus, removal of the leptin receptor should decrease bone parameters as was observed in 
our LysM
Cre+F/F
 52 week old females.  Conversely, the negative association between 
circulating leptin and BMD in males would point toward increases in bone parameters 
after receptor ablation as was also noted in our animals.  Though it is not yet possible to 
completely ascribe the effects of leptin on post-natal bone remodeling to the macrophage, 
this mouse model provides compelling evidence for the existence of a novel leptin-
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responsive myeloid osteoimmunologic intermediate.  This is also the first leptin 
transgenic mouse model to mimic the human condition with a divergent gender-specific 
phenotype.  Based on our findings, we hypothesize that with age, leptin receptors on the 
myeloid lineage may play a role in leptin-regulated maintenance of bone mass.   
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CHAPTER 3 
LEPTIN FUNCTIONS PERIPHERALLY TO REGULATE DIFFERENTIATION 
OF MESENCHYMAL PROGENITOR CELLS 
 
3.1 Summary 
  
Leptin functions through a well-documented central neuroendocrine pathway to regulate 
bone mass.  However, the ability of leptin to modulate bone mass through a peripheral 
mechanism has been debated due to conflicting in vitro results and lack of sufficient in 
vivo models. We utilized mice with loxP sites introduced into the long-form leptin 
receptor (ObRb) gene to determine how leptin regulates mesenchymal progenitor cell 
(MPC) differentiation and osteoblast function in vitro and in vivo. Rapid phosphorylation 
of Stat3 after leptin treatment of bone marrow stromal cells (BMSCs) from mice with 
conditional deletion of ObRb in macrophages (LysM
Cre+F/F
) confirmed expression of 
functional leptin receptors by BMSCs.  Adenovirus-Cre mediated disruption of ObRb in 
primary stromal cells decreased mineralization while increasing adipogenesis.  In 
contrast, BMSCs harvested from leptin-signaling deficient ob/ob or db/db mice showed 
increased mineralization.  To determine the physiologic relevance of these differences, 
mice with cell-specific deletion of ObRb in mesenchymal precursors (3.6
Cre+F/F
) or 
osteoblasts (2.3
Cre+F/F
) were generated.  Though the 2.3
Cre+F/F
 mice were grossly normal, 
the 3.6
Cre+F/F
 mice displayed mild obesity that was not attributed to food intake.  Femurs 
of 3.6
Cre+F/F 
animals showed a 58-61.9% increase in trabecular bone volume and a 65.5-
74% increase in bone mineral density.  Cortical volume and mineral content were also 
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increased 18-22%.   Primary 3.6
Cre+F/F 
BMSCs recapitulated the high mineralization 
phenotype of ob/ob and db/db BMSCs.  We conclude that leptin may have multiple 
peripheral roles depending on the differentiation state of MPC.  Leptin (1) helps maintain 
MPCs in an undifferentiated state and (2) promotes mineralization of more differentiated 
osteoblasts. 
 
3.2 Introduction 
Leptin, named after the Greek ‘leptos’ meaning ‘thin’, was discovered in 1994 during the 
analysis of a colony of spontaneously obese mice (Zhang, Proenca et al. 1994).  This 
16kDa cytokine has since been found to play a prominent role in regulation of energy 
metabolism and appetite (Pelleymounter, Cullen et al. 1995; Breslow, Min-Lee et al. 
1999; Cohen, Zhao et al. 2001).  Many secondary functions of leptin have also been 
uncovered (Myers 2004), including modulation of immune cell responses (La Cava and 
Matarese 2004) and maintenance of bone mass (Ducy, Amling et al. 2000; Steppan, 
Crawford et al. 2000; Hamrick, Della-Fera et al. 2005).  The ability of leptin to regulate 
bone formation through peripheral mechanisms has been debated due to conflicting in 
vitro results and a lack of sufficient in vivo models.  The challenge to study the  
peripheral effects of leptin with conditional regulated gene recombination (Cre-loxP) 
systems was proposed in 1998 (Friedman and Halaas 1998), but these experiments were 
not possible until the recent generation of a mouse model with loxP sites flanking the 
Jak2 signaling component of the long-form leptin receptor (ObRb) (McMinn, Liu et al. 
2004).  To help clarify the controversy of leptin’s peripheral actions on bone through 
regulation of mesenchymal progenitor cell (MPC) differentiation and osteoblast function 
 40 
we have used this model and generated three cell-specific knockouts of ObRb using 
LysM-Cre (‘macrophage’), Col2.3-Cre (‘osteoblast’) and Col3.6-Cre (‘MPC’) mice.  
 
Previous research demonstrates two mechanisms of leptin regulation of bone mass.  First, 
elegant in vivo studies support the central hypothesis which states that binding of leptin to 
ObRb in the hypothalamus can stimulate bone loss by regulating osteoblast activity 
through the sympathetic nervous system (Ducy, Amling et al. 2000; Takeda, Elefteriou et 
al. 2002; Elefteriou, Ahn et al. 2005).  Conversely, the peripheral hypothesis postulates 
that there are mechanisms through which local leptin can directly regulate bone formation 
by acting on cells in the bone marrow.  The existence of such mechanisms has been 
explored by multiple groups who have compiled key pieces of evidence.  For example, 
leptin receptors are expressed on the surface of human BMSCs (Hess, Pino et al. 2005) 
and recombinant leptin stimulation of human BMSCs in vitro has been shown to promote 
mineralization and partly inhibit adipogenic differentiation (Chang, Shih et al. 2006).  It 
has further been demonstrated in vitro that BMSC fate decisions can be regulated by 
suppression of leptin expression after addition of adipogenic factors (Yang, Tsay et al. 
2008).  Lastly, in vivo, peripheral (subcutaneous or intra-peritoneal) delivery of supra-
physiologic doses of leptin to leptin-deficient ob/ob mice resulted in a >30% increase in 
fluorochrome-labeled tibial endosteal surface and an 84.2% increase in distal femoral 
trabecular mineral content respectively (Steppan, Crawford et al. 2000; Hamrick, Della-
Fera et al. 2005).  Despite this evidence, the existence of physiologically relevant 
peripheral mechanisms is debated due to conflicting studies that have failed to 
demonstrate pro-osteogenic effects of leptin stimulation of primary mouse osteoblast 
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cultures (Ducy, Amling et al. 2000) and one in vivo publication with osteoblast-specific 
ObRb deletion that lacked significant differences in vertebral bone mass (Shi, Yadav et 
al. 2008).  Though conflicting, these studies have laid the groundwork for a more in-
depth examination of leptin’s peripheral actions with additional delineation of effects on 
primitive MPCs and more differentiated osteoblast populations.   
 
The true mesenchymal stem cell (MSC) is an elusive in vivo precursor to mesenchymal 
lineage cells such as osteoblasts, adipocytes, and chondrocytes.  MSCs have been 
identified in tissues including bone marrow (Friedenstein, Deriglasova et al. 1974), 
adipose (Zuk, Zhu et al. 2001), and dental pulp (Gronthos, Mankani et al. 2000).  Though 
many groups have focused on characterizing the MSC, specific cell surface markers have 
not been identified (Bianco, Riminucci et al. 2001; Gronthos, Franklin et al. 2001).  Thus, 
our methods for in vitro isolation date back to the 1970s (Friedenstein, Deriglasova et al. 
1974; Friedenstein, Gorskaja et al. 1976) and rely on the adherence of a subpopulation of 
cells to tissue culture plastic and subsequent passaging to enrich for MSCs (Aust, Devlin 
et al. 2004).  In vivo the MSC is defined as a multipotent cell that undergoes self-renewal 
until stimulated to differentiate into a daughter lineage.  Culturing these cells in vitro 
results in cells that are more differentiated and proliferative, yet not fully lineage 
committed.  Thus, studies which disrupt gene expression in vitro may result in a 
phenotype that is different than effects found when the gene is deleted in vivo.  In 
recognition of the limited knowledge of the ‘true’ MSC, this report will use the term 
mesenchymal progenitor cell (MPC) to refer to the in vivo precursor populations targeted 
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by Col3.6-Cre and bone marrow stromal cells (BMSCs) or adipose-derived stromal cells 
(ADSCs) to refer to MSCs that have been isolated and cultured in vitro. 
 
Analysis of current models of leptin signaling deficiency such as the ob/ob mouse (leptin 
deficient) and the db/db mouse (ObRb deficient) are limited by secondary complications 
of diabetes and obesity. Mutant mice display a phenotype of uncontrolled eating and 
rapid weight gain.  They also exhibit hyperphagia, glucose intolerance, elevated plasma 
insulin, subfertility, impaired wound healing, and both low (femoral) and high (vertebral) 
trabecular bone mass (Charlton 1984; Hamrick, Pennington et al. 2004).  To circumvent 
these systemic complications we utilized a mouse model with loxP sites flanking exon 17 
of the ObRb gene, deletion of this gene segment by Cre recombinase terminates receptor 
function (McMinn, Liu et al. 2004).  This study was designed to critically evaluate the 
ability of leptin to modulate differentiation of MPCs and the function of their osteoblast 
progeny.  We hypothesized that leptin exerts differential effects on lineage committed 
cells such as osteoblasts when compared to their more primitive MPC precursors.  To 
clarify these differences we have used in vitro adenovirus Cre and in vivo Col2.3-Cre 
(‘osteoblast’) and Col3.6-Cre (‘MPC’) mediated recombination of ObRb to explore the 
inherent role of physiologic, circulating leptin in bone formation and maintenance. 
 
3.3 Materials and Methods 
Primary Cell Culture 
BMSCs were harvested as described previously (Krebsbach, Kuznetsov et al. 1997) with 
slight modification.  Femora, tibiae, and humeri were dissected free of surrounding 
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muscle.  Marrow was removed with phosphate buffered saline (PBS) and filtered through 
a 70µm cell filter. The marrow content of 6-9 bones was plated into a 75-cm
2
 culture 
flask in BMSC growth medium (α-Modified Eagle’s Medium (α-MEM;  
Invitrogen/Gibco), 10% fetal bovine serum (Gibco, Lot no.451459), 100U/ml penicillin, 
100mg/ml streptomycin sulfate (Gibco Cat:15140), 100nm dexamethasone (Sigma 
Cat:D8893)).  To harvest adipose-derived stromal cells (ADSCs) intra-abdominal and 
paralumbar fat pads were collected, washed with PBS, and minced.  Minced adipose was 
incubated for one hour at 37
o
C in α-MEM + 0.2% Collagenase II (Gibco Cat:17101).  
ADSCs were pelleted at 1100rpm for 10 minutes at 4
o
C and plated at 6-8 million cells per 
10cm plate in ADSC growth medium (Dulbecco's Modified Eagle Medium (DMEM, 
Invitrogen/Gibco), 10% fetal bovine serum (Gibco, Lot no.451459), 100U/ml penicillin, 
100mg/ml streptomycin sulfate).  Cells were cultured at 37°C in an atmosphere of 100% 
humidity and 5% CO2. Colonies of adherent cells were formed by 11-14 days. The 
colonies were harvested and the sub-cultured cells were re-plated at 15,000 cells/cm
2
.    
 
PCR 
RNA was harvested using Trizol reagent (Invitrogen Cat:15596) and 0.3 to 1µg of total 
RNA was processed using the SuperScript
TM
 First-Strand RT-PCR kit (Invitrogen 
Cat:12371) to generate cDNA.  Leptin receptor expression was analyzed as previously 
reported (Lamghari, Tavares et al. 2006). GAPDH primers were used as a loading 
control, GAPDH_F: TTCCAGTATGACTCCACTCACGGCAAAT; GAPDH_R: 
TGGTGAAGACACCAGTAGACTCCACGAC.  Genomic DNA was harvested using the 
DNeasy Blood & Tissue Kit (Qiagen Cat:69506).  Expression of osteocalcin was 
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determined with computed threshold method qPCR using SYBR® Green PCR master 
mix (Applied Biosystems Cat:4309155) with GAPDH as a loading control.  OCN_F: 
CAAGCAGGGTTAAGCTCACA; OCN_R: GGTAGTGAACAGACTCCGGC; 
GAPDH_F: TGAAGCAGGCATCTGAGGG; GAPDH_R: 
CGAAGGTGGAAGAGTGGGAG. 
 
Western Blot 
Protein was harvested using NP-40 lysis buffer (10% glycerol, 1% NP-40, 50mM Tris 
pH7.4, 200mM NaCl, 2mM MgCl2, 1mM PMSF, 1xProtease Inhibitor Cocktail (Sigma 
Cat:P8340)) + phosphatase inhibitors (Roche Cat:04906845001).  Cells were washed 
with cold PBS + phosphatase inhibitors, collected and pelleted at 4
o
C.  Cell pellets were 
resuspended in 50-100µL of lysis buffer and incubated for 30min on ice.  Protein 
concentration was measured at 595nm with Bio-Rad protein assay dye concentrate 
(Cat:500-0006).  Protein extracts (50 µg) were boiled in 2x SDS sample buffer 10min and 
separated on a 10% Tris-HCl polyacrylamide gel (Bio-Rad).  Protein was transferred to 
PVDF membranes using a wet transfer system (Bio-Rad Cat:170-3930).  Membranes 
were blocked in 5% milk (Bio-Rad Cat:170-6404) one hour and probed overnight with 
1:500 Stat3 (Cell Signaling Cat:9132), 1:500 P-Stat3 (Cell Signaling Cat:9131), or 
1:1000 GAPDH (Chemicon® International Cat:MAB374). Signals were amplified with 
1:1500 HRP-conjugated secondary antibody (Santa Cruz Biotechnology) and 
SuperSignal® West Pico Chemiluminescent Substrate (Thermo Scientific, Pierce 
Product) and developed using film exposure. 
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Adenoviral Transduction 
Passage one BMSCs were plated at a density of 15,000cells/cm
2
 in T75 flasks.  After four 
hours virus was added at 800 multiplicity of infection (MOI) for BMSC or 400 MOI for 
ADSC in 4mL α-MEM+0.5% FBS.  Complete media was added after four hours.  
Adenovirus was used in accordance with NIH guidelines and obtained from the 
University of Michigan vector core (Ann Arbor, Michigan, USA).  Adenovirus 
expressing cre recombinase, harvest date 2/19/09, viral titer 2.40E11 PFU/mL.  
Adenovirus CMVpLpA.dlE3 #1 (AdBlank), harvest date 9/18/01, viral titer 1.30E11 
PFU/mL.  
     
In vitro Mineralization Assay 
Primary BMSCs in passage 2-3 were used for this assay.  Cells were plated in 12-well or 
6-well plates at 25,000-30,000 cells/cm
2
.  Plated cells were allowed to grow to 
confluence in complete medium for 2-4 days.  After reaching confluence cells were 
cultured in osteogenic medium (BMSC Growth Medium+100nm dexamethasone (Sigma 
Cat:D8893), 10mM beta-glycerophosphate (Sigma Cat:G9891), and 50µm ascorbic acid 
2-phosphate (Sigma Cat:A8960)) for up to 14 days.  Cells were fixed with 70% ethanol at 
4
o
C for one hour, rinsed with water, stained for 10 minutes in 40mM, pH 4.2 alizarin red, 
and washed extensively with water.  Dye was eluted in 10% w/v hexadecylpyridinium 
chloride monohydrate (Wako, Japan) in 10mM sodium phosphate pH 7.0 and 
concentration determined by absorbance measurement at 562nm.   
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In Vitro Adipogenic Differentiation 
ADSCs were plated at 30,000 cells/cm2 and grown to confluence for two days.  Cells 
were induced with adipogenic medium (ADSC Growth Medium+ 50µM 
Isobutylmethylxanthine (Sigma Cat:I7018), 1µM dexamethasone (Sigma Cat:D8893, 
167nM insulin (Sigma Cat:I5500), and 5µg/mL Troglitazone (Cayman Chemical 
Cat:71750)) for two days.  Adipogenic maintenance media (ADSC Growth Medium+ 
167nM insulin (Sigma Cat:I5500)) was then added for two days.  This process of 
induction media followed by maintenance media was repeated once.  Cells were then 
fixed in zinc buffered formalin (Z-fix, Anatech LTD, Battle Creek, MI) for one hour and 
stained with Oil Red O solution (Sigma Cat:O0625).  Dye was eluted in 100% 
isopropanol and quantified at 500nm.   
 
Animals 
All procedures were approved by the University Committee on the Use and Care of 
Animals (UCUCA).  Col2.3-Cre and Col3.6-Cre mice were obtained from Dr.Fei Liu 
(University of Michigan) (Liu, Woitge et al. 2004).  LysM-Cre mice were obtained from 
Jackson Laboratory (Bar Harbor, Maine, USA Cat:004781) (Clausen, Burkhardt et al. 
1999).   Flox/Flox Jak2-ObRb mice were obtained from Dr.Martin Myers (University of 
Michigan) with permission of Dr.Streamson Chua (Columbia University) (McMinn, Liu 
et al. 2004). Breeding cages contained one male with two females.  Pups were genotyped 
via PCR analysis of tail biopsy DNA with primers as reported previously (McMinn, Liu 
et al. 2004).    Deletion of the floxed allele was determined using the three-primer system 
designed by McMinn et al (McMinn, Liu et al. 2004).  Analysis of food intake was 
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performed daily for one week.  Mice were housed 2-3 animals per cage, mass of chow 
was determined every 24 hours, chow intake was averaged per housed animals to 
determine daily intake.   
 
Blood Collection and Serum Analysis  
Blood was collected from the mice by nicking the lateral tain vein and pooling blood 
drops into BD Microtainer® tubes (New Jersey, USA).  Blood was allowed to clot at 
room temperature for 30-45 minutes.  Samples were spun at 3000rpm for 10min at 4
o
C 
and serum supernatant removed.  Analysis of serum chemistries was performed by the 
Animal Diagnostic Laboratory of the University of Michigan (Ann Arbor, Michigan, 
USA).  For glucose and cholesterol analyses animals were placed on a 6 hour fast prior to 
serum collection.  Leptin analysis was performed using an ELISA assay kit as described 
for serum leptin (R&D Systems Cat: MOB00). 
 
Comprehensive Lab Animal Monitoring System (CLAMS) and Body Composition 
Analysis 
Measurements and analysis were performed by the University of Michigan Animal 
Phenotyping Core with approval by the University Committee on the Use and Care of 
Animals (UCUCA).  Body composition was determined using Nuclear Magnetic 
Resonance based analysis with a Minispec LF90II (Bruker, Optics) to quantify percent 
fat, lean mass, and fluid in live, conscious animals.  For CLAMS analysis, mice were 
single-housed in an open-circuit calorimetry system capable of simultaneous monitoring 
of whole animal oxygen consumption, carbon dioxide production, spontaneous activity 
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(photocell detection with X and Z coverage), and food intake.  Measurements for each 
parameter were recorded every 10-20 minutes for 72 hours.        
 
MicroCT  
Femurs were wrapped in 70% ethanol-soaked gauze and scanned using a vivaCT 40 µCT 
system (Scanco Medical, Switzerland) with an isotropic voxel size of 10.5µm (55 kVp, 
145µA, 1000 projections per 180 degrees, 200 ms integration time). 2D transverse slices 
were reconstructed into 2048x2048 pixel matrices. Cortical bone parameters were 
measured by analyzing 50 slices (0.525mm) of the mid-diaphysis. This region was 
defined to be the central portion between the proximal and distal ends of the femur. A 
semi-automated contouring method was used to determine the outer cortical bone 
perimeter. Briefly, a user-defined contour was drawn around the cortical bone perimeter 
of the first slice. This initial estimate is then subjected to automated edge detection. This 
semi-automated contour then serves as the initial estimate for the second slice, and the 
automated contouring process continues for all 50 slices. A fixed, global threshold of 375 
(1/1000 gray scale) corresponding to 635.9 mg of HA/ml was used to distinguish cortical 
bone from soft tissue and marrow. Trabecular bone parameters were measured by 
analyzing 101 slices (1.06mm) of the distal metaphysis. Briefly, the distal end of the 
analysis region was chosen to be 0.105 mm proximal to the primary spongiosa in the 
marrow cavity. This assured that only trabecular bone was analyzed. Starting at this 
image, a user-defined contour was drawn to include only the marrow cavity and exclude 
any cortical bone. User-defined contours were drawn every 10 images (0.105mm) and an 
automated morphing program was used to interpolate the contours for all images in 
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between. A fixed, global threshold of 230 (1/1000 gray scale) corresponding to 321.6mg 
of HA/ml was used to distinguish trabecular bone  from soft tissue and marrow. For both 
analyses, a Gaussian low-pass filter was used (σ=0.8, support=1).  
 
Statistics and Image Editing 
A two-tailed, homoscedastic t test was used to determine any difference between control 
and experimental groups. Values are reported as the mean +/- the standard deviation.  
P<0.050 was considered statistically significant.  P<0.100 was considered to represent a 
non-significant trend.  In images with ‘intact’ and ‘deleted’ bands lanes were cropped 
from the same parent gel.  Brightness and contrast were optimized equally across all 
lanes for improved visibility.  
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3.4 Results 
Primary bone marrow stromal cells (BMSCs) express functional ObRb  
Primary BMSCs were harvested from wild type C57BL/6J mice and analyzed for 
expression of leptin receptor mRNA at passage two (P2).  Consistent with previous 
reports in human BMSCs (Hess, Pino et al. 2005) and mouse clonal MC3T3-E1 
osteoblasts, (Lamghari, Tavares et al. 2006) both short form ObRa and long form ObRb 
leptin receptors were expressed as the progenitor cells differentiated to mature osteoblasts 
for 7, 14, or 21 days (Figure 11).  Since primary BMSCs are a heterogeneous population 
that is contaminated by cells of the macrophage lineage, we generated a mouse model 
with floxed ObRb deletion driven by the LysozymeM locus (LysM
F/F
) to disrupt ObRb 
function in macrophages (Clausen, Burkhardt et al. 1999).  Cre-lox recombination is a 
tool that is used to mediate site-specific recombination of genomic DNA (Sauer and 
Henderson 1988).  DNA sequences that are flanked by loxP nucleotide sequences or 
‘floxed’ are susceptible to deletion and recombination by the enzyme Cre recombinase.  
When expression of Cre is placed under the control of a specific promoter, such as LysM, 
gene deletion can be limited to the cell populations where that promoter is expressed.  In 
our experiments the flox sites were designed to flank exon 17 of ObRb.  When probed 
with primers designed to surround this exon, cre-mediated deletion of the segment was 
determined based on the appearance of a shorter ~200bp PCR band when compared to 
the intact 646bp band (Figure 11).  Stimulation of marrow derived monocytes from these 
mice with 50ng/mL M-CSF for two days resulted in recombination of the ObRb locus in 
macrophages in vitro (Figure 11).  As expected, culture of primary BMSCs from LysM
F/F
 
mice demonstrated that macrophage contamination of BMSC cultures decreased with 
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passaging of the cells (Figure 11).  Primary BMSCs (P2) derived from LysM
F/F
 mice 
were stimulated with 1000ng/mL leptin for 0, 5, 10 or 20 minutes and downstream 
phosphorylation of Stat3 (P-Stat3) was analyzed.  In response to leptin stimulation, rapid 
induction of P-Stat3 was observed after 5-10 minutes that could be attributed to the non-
macrophage portion of the primary BMSC preparation (Figure 12).   
ObRb
ObRa
GAPDH
WT BMSC
0          7           14          21
WBM      Mac P1          P2         P3
LysMCre+F/F BMSC
Intact
Deleted
A
B
ObRbFlox
ObRb∆17
16 17 17’ 18a
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16 18a
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C
17’
 
Figure 11. Primary bone marrow stromal cells (BMSCs) express ObRb. (A) PCR analysis of long-form 
(ObRb) and short-form (ObRa) leptin receptor. RNA from C57BL/6J (WT) P2 BMSCs. (B) Diagram of 
anticipated PCR products from intact or cre-recombined (deleted) genomic DNA.  (C) LoxP recombination 
in genomic DNA from whole bone marrow (WBM), primary macrophage (Mac) and passage one to 
passage 3 (P1-P3) BMSC from LysM
Cre+F/F
 mice.  WT: wild type.  GAPDH: glyceraldehyde-3-phosphate 
dehydrogenase.  Credit: (Scheller, Song et al. 2010).  
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Figure 12. Primary bone marrow stromal cell (BMSC) ObRb responds to leptin with phosphorylation of 
Stat3.  P-Stat3 induction after 1000ng/mL leptin administration for 0 to 20 minutes.  The ratio of P-Stat3 to 
Stat3 was quantified using densitometry and fold induction determined with time 0 normalized to 1.0.  
N=3.  *: statistically significant over control time zero.  GAPDH: glyceraldehyde-3-phosphate 
dehydrogenase.  Stat3: signal transducer and activator of transcription 3.  Credit: (Scheller, Song et al. 
2010).    
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Knockout of ObRb in vitro decreases mineralization and increases adipogenesis of 
primary stromal cells 
To evaluate the significance of endogenous leptin production in vitro, primary BMSCs 
were harvested from long bones of control mice harboring the ObRb loxP mutation.  
Cells were treated at P1 with adenovirus expressing Cre recombinase (AdCre) or a non-
functional poly-L-poly-A sequence (AdBlank) and monitored for ObRb gene deletion.  
Complete recombination of the loxP site occurred after AdCre treatment (Figure 13, 
Figure 14).  Treated BMSCs were harvested and re-plated at a density of 25,000 cells/cm
2
 
in 12-well plates and induced to differentiate toward osteoblasts.  AdCre treated cells 
exhibited significantly less in vitro mineral deposition at Day 7 of osteogenic culture that 
was equalized by Day 14 (Figure 13).  This deletion study is the converse of previous 
experiments that have added leptin directly to primary BMSCs in vitro and observed an 
increase in mineralization (Chang, Shih et al. 2006).  Similarly, primary ADSCs were 
harvested from para-lumbar and intra-abdominal fat pads and treated with AdCre or 
AdBlank as described above.  Ablation of ObRb function increased the adipogenic 
differentiation of the confluent cell monolayers by 99.8+/-25% (Figure 14).  This is also 
consistent with previous results that have demonstrated inhibition of adipogenesis in vitro 
by recombinant leptin (Rhee, Sung et al. 2008).      
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Figure 13. Knockout of ObRb in vitro decreases the mineralization of primary bone marrow stromal cells. 
Alizarin red stain and stain quantification of BMSCs treated with adenovirus expressing Cre recombinase 
(AdCre) or adenovirus expressing an inert poly-L-poly-A sequence (AdBlank) at 800MOI.  Inset shows 
PCR of genomic DNA after virus treatment and confirms recombination of the loxP site.  Bands are 
cropped from the same gel.  N=3.  *: statistically significant over matched day.  Credit: (Scheller, Song et 
al. 2010).   
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Figure 14.  Knockout of ObRb in vitro increases the adipogenesis of primary adipose derived stromal cells 
(ADSCs).  Adipogenesis, Oil Red O stain, of ADSCs treated with adenovirus expressing Cre recombinase 
(AdCre) or adenovirus expressing an inert poly-L-poly-A sequence (AdBlank) at 400MOI.   Inset shows 
PCR of genomic DNA after virus treatment and confirms recombination of the loxP site.  Bands are 
cropped from the same gel.  N=4.  *: statistically significant over control.  Credit: (Scheller, Song et al. 
2010).   
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BMSCs obtained from mice with an absence of total body ObRb signaling show 
increased mineralization potential in vitro  
Surprisingly, while the in vitro disruption of leptin signaling resulted in reduced 
mineralization, primary BMSCs from leptin-deficient ob/ob and ObRb-deficient db/db 
mice showed a high mineralization phenotype.  At Day 14, mineralization of ob/ob and 
db/db cultures was increased by 50.7+/-6.4% or 45.1+/-5.4% respectively (Figure 15).  
Addition of 100ng/mL recombinant leptin to the medium failed to rescue the high 
mineralization phenotype (Figure 15).  Osteocalcin expression at Day 14 was also 
increased by 2.9+/-0.08-fold (ob/ob) or 2.4+/-0.23-fold (db/db) (Figure 15). Alkaline 
phosphatase activity was significantly higher per total protein in ob/ob but not db/db cells 
(Figure 15).  
 
Generation of transgenic mice expressing Col2.3-Cre or Col3.6-Cre and harboring the 
ObRb
F/F
 site  
To determine the physiologic relevance of the divergent in vitro mineralization patterns, 
we generated osteoblast (Col2.3) and MPC (Col3.6) cell-specific knockout mice.  The 
Col3.6 promoter is active in osteoblast precursors while the 2.3 promoter is active when 
cells differentiate to become osteoblasts (Liu, Woitge et al. 2004).   Mice harboring the 
ObRb
F/F
 site were mated with Col2.3-Cre ObRb
F/- 
or Col3.6-Cre ObRb
F/-
 mice to 
generate litters consisting of Cre-F/F, Cre-F/-, Cre+F/-, and Cre+F/F mice in a 1:1:1:1 
ratio.  Breeding conformed to expected Mendelian ratios, however, complete gene 
disruption was observed in a significant number of female pups and some of the males 
for both Col3.6-Cre and Col2.3-Cre litters (observation, not quantified).   
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Figure 15.  Bone marrow stromal cells (BMSCs) from ob/ob and db/db mice show increased 
mineralization.  (A) Alizarin red stained mineral after fourteen days in osteogenic media (OM) with or 
without 100ng/mL leptin. Mineral was quantified and normalized to total genomic DNA per well.  Passage 
2 BMSCs.  N=5-6.  (B) Quantitative PCR for osteocalcin (OCN) expression.  N=3.  (C) Alkaline 
phosphatase activity as measured by conversion of p-nitrophenol phosphate to nitrophenol, normalized to 
total protein. N=3.  WT: wild type.  *: statistically significant over matched wild type.  Credit: (Scheller, 
Song et al. 2010).   
This is consistent with previous reports of sporadic germline recombination (Cochrane, 
Clark et al. 2007) when using the Col2.3 and Col3.6 promoters.  Complete knockout 
(KO) mice were easily identified phenotypically by their frank obesity and genetically by 
100% band excision in harvested DNA (Figure 16).  Tissue analysis of genomic DNA 
revealed some recombination in all tissues of 3.6
Cre+F/F
 mice with the highest deletion rate 
in adipose, tendon, and calvaria (Figure 17).  Consistent with previous reports, the 
majority of in vitro primary 3.6
Cre+F/F
 BMSCs harbored the deleted form of the ObRb 
locus (Liu, Woitge et al. 2004) (Figure 17).  We speculate that the background 
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recombination in 3.6
Cre+F/F
 whole tissues can be attributed to expression of Col3.6 in 
tissue-associated MPC or vascular endothelial cells.   Recombination in 2.3
Cre+F/F
 mice 
was highest in muscle, calvaria, and whole marrow (Figure 17).   
A
Control
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Knock-Out
B
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Deleted
Control                  Knock-Out 
 
Figure 16.  Germline knockout of ObRb results in significant obesity.  (A) Representative mouse 
photographs of control Cre negative and complete ObRb knockout mice.  (B) Genomic DNA PCR 
confirming complete loxP recombination of genomic DNA in bone marrow macrophages derived from the 
knockout animals and intact ObRb the controls.  Bands are cropped from the same gel and replicate 
duplicate samples.  Credit: (Scheller, Song et al. 2010; Scheller, Hankenson et al. 2011).      
The gross phenotype of 2.3
Cre+F/F
 mice was identical to 2.3
Cre-
 controls.  The 3.6
Cre+F/F
 
mice demonstrated mild obesity that remained statistically significant after approximately 
12 weeks of age (Figure 18).  Body composition analysis of 16 week old female mice 
revealed that the mass increase was due predominantly to increased adiposity, however, 
total lean and fluid mass were also significantly increased (Figure 19).   
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Figure 17. Characterization of loxP recombination in mice expressing Col2.3-Cre or Col3.6-Cre and 
harboring the ObRb
F/F
 site.  (A) Representative PCR of tissue genomic DNA from 12 week old animals.  
(B) PCR of whole bone marrow (WBM) and passage one to passage three (P1-P3) bone marrow stromal 
cells (BMSCs) from 3.6
Cre+F/F
mice.  Cre-: P1 BMSCs harvested from mice lacking Col3.6 driven Cre 
recombinase expression.  Bands are cropped from the same gel.  Credit: (Scheller, Song et al. 2010). 
This translated to a significant increase in percent body fat, decrease in lean mass, and no 
change in percent fluid (Figure 19).   Mice were examined for alterations in fasting serum 
chemistries including cholesterol, calcium, ALT, albumin, alkaline phosphatase, amylase, 
blood urea nitrogen, creatinine, hemoglobin, phosphate, total bilirubin, total protein, 
glucose, and leptin (Table 4).  The only significant differences in these values between 
the 3.6
Cre-
 and 3.6
Cre+ F/F
 mice were a slight increase in serum calcium (within normal 
range), a small increase in total protein driven by an increase in albumin and a significant 
elevation of serum leptin (Table 4).  Thus, unlike the complete knockout mice, 3.6
Cre+ F/F
 
mice were not diabetic and had no significant alterations in liver or kidney function.   
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Labs Cre- Cre+ F/F p value
Cholesterol (mg/dL) 142.3 156.6 0.137
Alkaline Phosphatase (units/L) 41 49 0.101
Alanine aminotransferase (units/L) 51.2 49.4 0.777
Amylase (units/L) 2581 2411 0.389
Blood Urea Nitrogen (mg/dL) 22.5 21.3 0.645
Calcium (mg/dL) 8.66 9.3 0.041
Creatanine (mg/dL) 0.275 0.3 0.437
Phosphate (mg/dL) 9.425 8.4 0.392
Total Bilirubin (mg/dL) 0.825 0.75 0.368
Albumin (g/dL) 2 2.425 0.047
Globulin (g/dL) 2.85 2.875 0.171
Total Protein (g/dL) 4.725 5.3 0.021
Fasted Glucose (mg/dL) 150.3 149.8 0.969
Leptin (ng/mL) 4.8 44.5 0.006
Col3.6 Serum Chemistries
 
Table 4.  Serum chemistries of 3.6
Cre-
 and 3.6
Cre+F/F
 mice.  Analysis reveals a significant increase in 
circulating calcium in the 3.6
Cre+F/F
 mice.  There is also a significant increase in total protein that is driven 
by increases in albumin.  N=4-6.  Credit: (Scheller, Song et al. 2010). 
 
Metabolic analysis of 3.6
Cre+F/F
 mice  
Food intake of 42 week old mice was monitored for one week.  No significant differences 
were observed between the three groups (Data Not Shown).  To enhance sensitivity of 
food intake monitoring and examine additional metabolic parameters, 3.6
Cre-
 and 
3.6
Cre+F/F
 females at 16 weeks of age were subjected to three day metabolic analysis.  
Similar to the aged males, the output did not reveal a statistically significant increase in 
intake of the 3.6
Cre+F/F 
animals when compared to controls (Figure 20).  Total activity was 
similarly unchanged between groups (Figure 20).  The only consistent difference was a 
highly significant decrease in oxygen consumption per body mass per hour in the 
3.6
Cre+F/F
 animals (Figure 20).  This was likely driven by the increased mass of the 
3.6
Cre+F/F
 mice and disappeared when normalized to lean instead of total body mass 
(Figure 20).               
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Figure 18.  Gross phenotype of 3.6
Cre+F/F
 mice.  (A) Representative photo of 12 week old male 3.6
Cre-
 and 
3.6
Cre+F/F
 mice showing increase in peripheral adiposity and body size.  (B) Mass of male transgenic mice 
from 3 to 38 weeks of age.  *: significant over matched time point 3.6
Cre-
.  N=4-6.  Credit: (Scheller, Song 
et al. 2010); E.L Scheller, unpublished data.  
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Figure 19.  Minispec body composition analysis of 3.6
Cre-
 and 3.6
Cre+F/F
 mice.  Female mice at 16 weeks of 
age were analyzed with Nuclear Magnetic Resonance based imaging on a Minispec LF90II (Bruker, 
Optics) to quantify percent fat, lean mass, and fluid in live, conscious animals.  (A) Absolute mass of whole 
body, fat, lean mass, and fluid.  (B) Percent fat, lean, and fluid mass relative to whole body weight.  3.6
Cre-
 
N=10, 3.6
Cre+F/F
 N=7.  *: statistically significant relative to 3.6
Cre-
.  Credit: E.L Scheller, unpublished data.   
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Figure 20.  Comprehensive lab animal monitoring system (CLAMS) analysis of 3.6
Cre-
 and 3.6
Cre+F/F
 mice.  
Mice were single-housed in an open-circuit calorimetry system capable of simultaneous monitoring of (A) 
food intake, (B) whole animal oxygen consumption (VO2), (C) spontaneous activity (photocell detection 
with X and Z coverage).  (D) Oxygen consumption was normalized to lean body mass.  Measurements for 
each parameter were recorded every 10-20 minutes for 72 hours.  3.6
Cre-
 N=10, 3.6
Cre+F/F
 N=7.  Credit: E.L 
Scheller, unpublished data. 
 
Contrasting bone phenotypes of 2.3
Cre+F/F
 and 3.6
Cre+F/F
 mice  
Femurs were dissected free of muscle and radiographed at 32kV for 45 seconds (Figure 
21).  Femoral microCT analysis revealed no difference in trabecular parameters of the 
2.3
Cre+F/F
 femurs (Table 5).  However, cortical parameters showed a non-significant trend 
(P<0.100) toward increased bone volume and bone area (Table 5).   
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Trabecular 2.3Cre- 2.3Cre+F/F p value
Bone Volume (mm^3) 0.523+/-0.063 0.462+/-0.103 0.245
Bone Volume Fraction (%) 22.4+/-2.5 19.3+/-3.9 0.131
Tb. Number (1/mm) 5.24+/-0.42 4.90+/-.41 0.183
Tb. Thickness (mm) 0.060+/-0.003 0.058+/-0.004 0.393
Mineral Density of Total Volume (mg HA/ccm) 181+/-22 156+/-34 0.171
Total Mineral Content (mg HA) 422+/-60 373+/-88 0.288
Bone Mineral Content (mg HA) 436+/-61 383+/-84 0.239
Cortical 2.3Cre- 2.3Cre+F/F p value
Total Volume (mm^3) 0.86+/-0.05 0.90+/-0.02 0.160
Bone Volume (mm^3) 0.398+/-0.017 0.416+/-0.016 0.099
Mineral Density of Total Volume (mg HA/ccm) 555+/-28 550+/-25 0.759
Total Mineral Content (mg HA) 478+/-18 493+/-21 0.221
Bone Mineral Content (mg HA) 467+/-17 481+/-20 0.221
Total Area (mm^2) 1.68+/-0.01 1.74+/-0.04 0.183
Bone Area (mm^2) 0.79+/-0.03 0.82+/-0.03 0.098
12 weeks Col2.3
 
Table 5.  Micro computed tomography analysis of 2.3
Cre-
 and 2.3
Cre+F/F
 femurs at 12 weeks. Trabecular and 
cortical bone parameters of male mice as determined by microCT.  N=6.  Credit: (Scheller, Song et al. 
2010). 
Due to the presence of significant differences, femurs of 3.6
Cre+F/F
 mice were analyzed at 
both 12 and 42 weeks of age.  At 42 weeks femur length was increased by 0.78+/-
0.02mm (5.5+/-0.16%) in male 3.6
Cre+F/F
 mice when compared to 3.6
Cre-
 controls (Figure 
21).  At both ages trabecular parameters including bone volume fraction (BVF) and 
mineral density of total volume (MD of TV) were significantly increased by 58-61.9% 
and 65.5-74% respectively (Table 6).  Increased cortical parameters at 12 weeks 
mimicked those present in complete knockout mice with an 18.3+/-1.7% and a 21.7+/-
2.2% increase in bone volume and total mineral content respectively (Table 6).  The 
decrease in femoral trabecular BVF and increased cortical parameters of our spontaneous 
complete KO mice recapitulates what has been reported previously for ob/ob mice 
(Hamrick, Pennington et al. 2004) (Table 7). 
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Figure 21.  Femoral imaging and length analysis of transgenic mice.  (A) Representative faxitron x-ray 
image of femurs from 12 week old Col2.3, Col3.6, and germline knockout (KO) mice.  Decreased length of 
the KO and increased length of the 3.6
Cre+F/F
 femurs relative to control can be noted.  (B) Quantification of 
femur length of 3.6
Cre-
 and 3.6C
re+F/F
 mice at 42 weeks.  N=6-8.  Credit: (Scheller, Song et al. 2010).    
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Trabecular Control Col3.6+ p value Control Col3.6+ p value
Bone Volume (mm^3) 0.380+/-0.099 0.684+/-0.099 0.006 0.270+/-0.111 0.416+/-0.123 0.056
Bone Volume Fraction (%) 16+/-4.1 25.9+/-3 0.011 9.1+/-3.5 14.4+/-4.2 0.035
Tb. Number (1/mm) 4.56+/-0.56 5.51+/-0.52 0.056 2.72+/-0.69 3.35+/-0.47 0.089
Tb. Thickness (mm) 0.056+/-0.003 0.065+/-0.003 0.005 0.058+/-0.006 0.064+/-0.007 0.154
Mineral Density of Total Volume (mg HA/ccm) 127+/-28 210+/-30 0.008 78+/-37 135+/-51 0.050
Total Mineral Content (mg HA) 300+/-66 552+/-92 0.004 229+/-109 389+/-147 0.059
Bone Mineral Content (mg HA) 312+/-80 565+/-87 0.006 233+/-100 367+/-116 0.057
Cortical Control Col3.6+ p value Control Col3.6+ p value
Total Volume (mm^3) 0.89+/-0.07 0.99+/-0.02 0.060 1.22+/-0.11 1.25+/-0.06 0.629
Bone Volume (mm^3) 0.398+/-0.012 0.471+/-0.046 0.012 0.552+/-0.047 0.593+/-0.064 0.238
Mineral Density of Total Volume (mg HA/ccm) 534+/-26 582+/-46 0.104 579+/-61 615+/-39 0.253
Total Mineral Content (mg HA) 473+/-28 576+/-58 0.013 705+/-70 768+/-69 0.145
Bone Mineral Content (mg HA) 467+/-25 554+/-51 0.015 687+/-62 744+/-73 0.169
Total Area (mm^2) 1.72+/-0.14 1.92+/-0.04 0.057 2.38+/-0.22 2.44+/-0.12 0.605
Bone Area (mm^2) 0.84+/-0.09 0.93+/-0.09 0.012 1.09+/-0.09 1.18+/-0.13 0.234
42 week Col3.612 week Col3.6
 
Table 6.  Micro computed tomography analysis of 3.6
Cre-
 and 3.6
Cre+F/F
 femurs at 12 and 42 weeks. Trabecular and cortical bone parameters of male mice as 
determined by microCT.  N=3-6.  Credit: (Scheller, Song et al. 2010
6
6
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Trabecular Control KO p value
Bone Volume (mm^3) 0.523+/-0.063 0.462+/-0.072 0.170
Bone Volume Fraction (%) 22.4+/-2.5 18.6+/-3.0 0.050
Tb. Number (1/mm) 5.24+/-0.42 4.75+/-0.36 0.071
Tb. Thickness (mm) 0.060+/-0.003 0.058+/-0.003 0.332
Mineral Density of Total Volume (mg HA/ccm) 181+/-22 163+/-19 0.190
Total Mineral Content (mg HA) 422+/-60 403+/-43 0.582
Bone Mineral Content (mg HA) 436+/-61 376+/-56 0.124
Cortical Control KO p value
Total Volume (mm^3) 0.86+/-0.05 0.99+/-0.08 0.008
Bone Volume (mm^3) 0.398+/-0.017 0.477+/-0.062 0.015
Mineral Density of Total Volume (mg HA/ccm) 555+/-28 594+/-25 0.036
Total Mineral Content (mg HA) 478+/-18 591+/-65 0.002
Bone Mineral Content (mg HA) 467+/-17 568+/-65 0.005
Total Area (mm^2) 1.68+/-0.01 1.93+/-0.15 0.009
Bone Area (mm^2) 0.79+/-0.03 0.94+/-0.12 0.014
12 week Complete Knockout
 
Table 7.  Micro computed tomography analysis of 2.3
Cre-
 and germline knockout (KO) femurs at 12 weeks. 
Trabecular and cortical bone parameters of male mice as determined by microCT.  N=4-6.  Credit: 
(Scheller, Song et al. 2010). 
 
Primary BMSCs from mice 3.6
Cre+ F/F
 mice have increased osteoblast and adipocyte 
differentiation potential in vitro 
To verify that deletion of ObRb in vivo results in an increased differentiation in vitro we 
harvested primary stromal cells from both 3.6
Control
 and 3.6
Cre+ F/F
 mice.  Mineralization of 
the BMSCs at P2 in vitro revealed a robust mineralization phenotype that mimicked that 
of BMSCs from ob/ob and db/db mice.  Mineralization was increased by 422+/-215% at 
Day 7 and 192+/-17% at Day 14 (Figure 22).  Differentiation of primary BMSCs also 
showed a 97.7+/-23.1% increase in adipogenic potential (Figure 23).  
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Figure 22. Knockout of ObRb in MPCs in vivo with Col3.6-Cre results in increased in vitro mineralization.  
Mineralization, alizarin red stain and quantification of passage two bone marrow stromal cells (BMSCs) 
from 3.6
Cre-
 and 3.6
Cre+F/F
 mice. Inset shows PCR of genomic DNA and confirms recombination of the loxP 
site.  Bands are cropped from the same gel.  N=3.  *: statistically significant over 3.6
Cre-
.  Credit: (Scheller, 
Song et al. 2010).   
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Figure 23.  Knockout of ObRb in MPCs in vivo with Col3.6-Cre results in increased in vitro adipogenesis.  
Adipogenesis, oil red o stain and quantification of passage two bone marrow stromal cells (BMSCs) from 
3.6
Cre-
 and 3.6
Cre+F/F
 mice. Inset shows PCR of genomic DNA and confirms recombination of the loxP site.  
Bands are cropped from the same gel.  N=3.  *: statistically significant over 3.6
Cre-
.  Credit: (Scheller, Song 
et al. 2010).   
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3.5 Discussion  
It is well established that leptin acts primarily through the hypothalamus to regulate 
weight gain through food intake (Pelleymounter, Cullen et al. 1995; Breslow, Min-Lee et 
al. 1999; Cohen, Zhao et al. 2001).  Generation of a mouse with conditional disruption of 
the long-form leptin receptor gene in the MPC and osteoblast has allowed us to begin to 
understand the physiologic contributions of peripheral leptin in bone.  We used a mouse 
with loxP sites flanking exon 17 of ObRb to critically evaluate physiologic regulation of 
bone formation by peripheral leptin in vitro and in vivo.  To do this, three transgenic 
mouse lines were generated with cell-specific knockout of ObRb function using the 
LysM, Col2.3 and Col3.6 promoters.  Use of the Col2.3 and Col3.6 promoters is 
somewhat limited by high levels (15-50%) of germline recombination that decreases the 
number of usable offspring (Cochrane, Clark et al. 2007) as well as non-specific 
expression of Col3.6 in tendon, skin, and muscle (Liu, Woitge et al. 2004).  However, 
both promoters have previously been used successfully (Lengner, Steinman et al. 2006; 
Gutierrez, Kong et al. 2008) and an alternative promoter that drives reliable 
recombination in the mesenchymal precursor compartment without also affecting 
neighboring bone cells is not yet available. 
 
The Col3.6 promoter is known to be expressed in multiple tissues including tendon, skin, 
calvaria, and long bone (Liu, Woitge et al. 2004).  Analysis with ROSA reporter mice 
shows widespread expression in the bone cavity that encompasses the osteocyte, 
osteoblast, and stromal fibroblast population with additional expression observed in some 
clustered areas of proliferative and hypertrophic chondrocytes (Liu, Woitge et al. 2004).  
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Adipose tissue was not analyzed in this previous publication, though our current study 
reveals high levels of recombination in the fat pads (Figure 17).  Since the Col3.6 
promoter mediates loxP recombination in osteoblasts, adipocytes, and some chondrocytes 
we believe that it likely deletes the gene a precursor population for these lineages, the 
MPC.  BMSC from Col3.6-Cre mice crossed with ROSA Cre-reporter mice in low-
density CFU-F cultures show high expression of Cre-recombinase in primitive colonies 
which is additional evidence that Col3.6 forces recombination at an early MPC-like level 
(Liu, Woitge et al. 2004).  Thus, we propose that recombination driven by Col3.6-Cre is 
one method that can be used to study effects of gene deletion on MPC function in vivo.  
However, it is still possible that an unidentified population of neurons express Col3.6 and 
that ObRb deletion in these cells is contributing to the 3.6
Cre+ F/F
 mouse phenotype.  When 
leptin receptors are completely deleted in the hypothalamus in vivo this results in 
decreased length and trabecular bone of the femur (Hamrick, Pennington et al. 2004).  
Since the 3.6
Cre+F/F
 mice have longer femurs with increased trabecular bone, it is not yet 
clear how non-specific brain recombination would contribute to the bone phenotype.  
However, future studies will continue to explore this possibility.  Col2.3 promoter 
expression is more restricted and shows deletion primarily in more differentiated 
osteoblasts (Liu, Woitge et al. 2004).  We have used the above premise to explore the 
contrasting in vitro mineralization phenotypes found in leptin-signaling deficient BMSCs 
that were generated in vitro (AdCre) or in vivo (ob/ob and db/db).   
 
When determining the ability of ob/ob and db/db cells to mineralize in vitro, an 
unanticipated finding was that despite decreases in femoral trabecular bone content in 
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vivo (Hamrick, Pennington et al. 2004) the cells actually mineralized more than their 
controls in vitro.  This was matched by increases in osteocalcin expression and for ob/ob, 
increases in alkaline phosphatase activity.  ALP activity is variable in murine BMSC 
cultures and we do not yet understand the significance, if any, of the non-significant 
differences between WT and db/db BMSCs.  This finding of high mineralization was 
initially assumed to be due to unknown systemic complications of diabetes and obesity.  
Addition of recombinant leptin did not reduce the mineralization of the cells to baseline 
levels implying that the starting population derived from ob/ob mice is unique when 
compared to WT.  Previous publications have shown that leptin is able to enhance 
mineralization at higher concentrations (0.6-1.2µg/mL) (Chang, Shih et al. 2006).  The 
systemically healthy 3.6
Cre+F/F
 ObRb mouse model which exhibited an opposite in vivo 
phenotype of increased trabecular BVF and BMD in the femur also showed increased 
mineralization potential in vitro similar to the ob/ob and db/db mice.  This suggests that 
in vivo the systemic environment is driving differentiation of the MPCs in opposite 
directions in the ob/ob (increased medullary fat) and 3.6
Cre+F/F
 (increased trabecular bone) 
mice.  Despite these differences in vivo, culture of the cells in vitro revealed uniform 
increased sensitivity to osteoblast differentiation.  In contrast, deletion of ObRb in 
cultured and passaged P2 BMSCs in vitro decreased mineralization.   We believe that this 
in vitro deletion occurs when mesenchymal lineage cells are fundamentally very different 
and more differentiated than the in vivo deletion that occurs in primitive in MPC of 
ob/ob, db/db and 3.6
Cre+F/F
 mice.  While an absence of leptin signaling in primitive cells 
results in MPC with enhanced differentiation potential, ObRb disruption in differentiated 
cells in vitro is inhibitory to osteoblast differentiation but promotes adipogenic 
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differentiation.  As observed with the 2.3
Cre+F/F
 mouse and one previous publication (Shi, 
Yadav et al. 2008), inhibition of leptin’s actions on osteoblasts does not appear to be 
physiologically relevant to trabecular bone parameters during states of healthy 
equilibrium in vivo.   
 
Even in the presence of intact leptin signaling, obesity can have significant effects on 
bone cell function in vitro and bone mass in vivo (Cao, Gregoire et al. 2009; Iwaniec, 
Dube et al. 2009).  Studies that have analyzed bone parameters in mice due to diet-
induced obesity observed increases in cortical parameters of the femur (Iwaniec, Dube et 
al. 2009) with no change (Iwaniec, Dube et al. 2009) or decreases (Cao, Gregoire et al. 
2009) in trabecular parameters.  These studies observed changes in obese mice of age 14-
25 weeks that were approximately 32-38g.  Despite being of comparable age and body 
mass to the diet-induced obese mice, our 3.6
Cre+F/F
 mice presented with statistically 
significant increases in trabecular bone parameters instead of decreases.  Consistent with 
previous results (Iwaniec, Dube et al. 2009), we also observed cortical changes in our 
3.6
Cre+F/F
 mice at 12 weeks that failed to persist and equalized by 42 weeks.  Thus, we 
conclude that the trabecular bone phenotype is due to ObRb deletion and not increased 
load bearing. 
 
Since systemic leptin is increased in the 3.6
Cre+F/F
 animals due to adipose accumulation, 
one must also consider the effects of leptin on osteoclast function.  It is possible that the 
high bone mass observed in these animals is related to inhibition of osteoclast 
differentiation or activity.  However, in vivo knockout of ObRb in osteoclast precursor 
 74 
macrophages with the LysM-Cre promoter did not change body mass or bone parameters 
at 12 weeks (Table 3).  In addition, published data do not support a consistent role for 
leptin in mature osteoclast function.  For example, even though ob/ob and db/db mice 
have over two-fold increase in osteoclast number the excretion of urinary 
deoxypyridinoline crosslink, a biochemical marker of bone resorption, was not impaired 
when compared to controls (Ducy, Amling et al. 2000).  Conversely, leptin deficient rats 
have increased osteoclast surface, but no increase in numbers (Tamasi, Arey et al. 2003).  
Isolation of primary bone marrow osteoclast progenitors from leptin-deficient mice 
showed no deficiency in osteoclast differentiation or their ability to form resorption 
lacunae on dentin (Ducy, Amling et al. 2000).  Other in vitro studies demonstrated that 
leptin partially inhibits osteoclastogenesis of primary mouse marrow cultures but did not 
affect bone resorption of mature osteoclasts (Cornish, Callon et al. 2002).   
 
Based on our data we propose a working model for peripheral leptin regulation of bone 
mass that includes divergent mechanisms depending on the differentiation state of the 
MPC (Figure 24).  Generally, it is thought that a factor that controls MPC differentiation 
to adipocytes will inhibit differentiation toward osteoblasts and vice versa.  However, in 
some situations a factor may block differentiation of primitive MPCs without regard for 
the downstream possibilities, in effect maintaining stemness.  Here, we demonstrate that 
leptin may be one of the factors that functions to maintain MPCs in an undifferentiated 
state.  Thus, in mice with leptin signaling deficient MPC there is enhanced bone 
formation and increased adipogenesis, and cells in vitro show increased differentiation to 
these fates.  Future studies will pursue this hypothesis and work to uncover any potential 
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Col3.6 expressing neurons that may contribute to the bone and metabolic phenotype.  
Though we do not yet understand the full implications of this finding, there are multiple 
clinical scenarios that should be tested to uncover its relevance.  For example, it has been 
previously reported that sites with high marrow fat content (and thus higher local leptin 
concentration) have a decreased rate of bone turnover (Wronski, Smith et al. 1981).  It is 
possible that leptin’s inhibition of MPC differentiation may play a role in this process.  
Or, perhaps limited fracture healing potential in obese individuals (Foulk and Szabo 
1995) with increased systemic leptin may be related to leptin’s limitation of de novo 
mesenchymal activation, osteoblast recruitment and subsequent matrix synthesis.  In the 
future we hope to address these questions and expand our molecular understanding of 
leptin’s regulation of MPC function.  In summary, we conclude that though the effect of 
leptin on mature osteoblast function may not be physiologically significant in vivo, leptin 
has previously unrecognized peripheral roles in bone that include regulation of MPC 
differentiation.      
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Figure 24.  Peripheral model of leptin action on MPCs and osteoblasts. Leptin (1) helps to maintain MPCs 
in an undifferentiated state and (2) promotes differentiation and mineralization of in vitro pre-osteoblasts 
and osteoblasts.  Credit: (Scheller, Song et al. 2010).   
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CHAPTER 4 
ECTOPIC EXPRESSION OF COL-2.3 AND COL-3.6 PROMOTERS IN THE 
BRAIN – ASSOCIATION WITH LEPTIN SIGNALING AND CONTRIBUTION 
TO THE 3.6
CRE+F/F
 PHENOTYPE 
 
4.1 Summary 
 
We have used the collagen 2.3 and 3.6 promoters to drive Cre expression for generation 
of conditional transgenic mutant mice.  Within the bone, Col3.6 is expressed by 
mesenchymal precursor cells (MPC) and their downstream progeny while Col2.3 is more 
osteoblast-specific.  Our generation of transgenic mice with Col2.3-Cre and Col3.6-Cre 
driven deletion of the long-form leptin receptor (ObRb) necessitated a thorough analysis 
of non-specific expression of these promoters in the central nervous system.  Both Col2.3 
and Col3.6 were capable of forcing loxP recombination in the brain as demonstrated by 
EGFP expression in ROSA reporter mice.  Expression of Col2.3 was limited to the 
central base of the brain near the third ventricle.  In contrast, robust expression of Col3.6 
was noted throughout the brain centering near the distal third ventricle, third ventricle, 
and aqueduct.  We subsequently analyzed co-localization of leptin-responsive P-Stat3 
neurons with Col3.6 expressing neurons.  Approximately 5-10% co-localization was 
noted in leptin-responsive brain areas such as the arcuate nucleus, dorsal medial 
hypothalamus, ventral premammillary nucleus, and lateral hypothalamus.  Injection of 
3.6
Cre+F/F
 ObRb knockout mice with leptin confirmed the presence of an intact P-Stat3 
response that was dampened in the lateral hypothalamus (p<0.050).  This test was done to 
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explore the contribution of neural leptin signaling to the bone phenotype of the 3.6
Cre+F/F
 
mice.  Our analysis indicates that neural ObRb deletion, while present, is likely not the 
sole driver of the femoral changes through traditional sympathetic circuits.   
 
4.2 Introduction 
We previously reported a significant increase in both femur length and trabecular density 
in mice with conditional deletion of the long-form leptin receptor (ObRb) driven by 
Col3.6-Cre (3.6
Cre+F/F
) (Scheller, Song et al. 2010).  No bone changes were noted in 
Col2.3-Cre driven ObRb knockout animals (2.3
Cre+F/F
).  The Col2.3 and Col3.6 promoters 
are derived from the full-length collagen 1A1 (Col1A1) (Krebsbach, Harrison et al. 
1993).  Col3.6 contains a 3.6kb fragment (-3521 to +115) of the Col1A1 gene.  Col2.3 
consists of approximately 2.3kb of Col1A1 DNA upstream of the transcription start site 
(Krebsbach, Harrison et al. 1993).  Col2.3-Cre is known to drive loxP recombination in 
the osteoblast and odontoblast populations (Kalajzic, Liu et al. 2002; Liu, Woitge et al. 
2004).  Col3.6-Cre in the marrow shows recombination in an earlier mesenchymal 
precursor cell (MPC) and its downstream progeny (Liu, Woitge et al. 2004).  There is 
also evidence that Col3.6-Cre induces non-specific recombination in other tissues 
including tendon, muscle, skin, and adipose (Liu, Woitge et al. 2004; Scheller, Song et al. 
2010). 
 
Leptin is an adipokine and central regulator of food intake and metabolism 
(Pelleymounter, Cullen et al. 1995).  Development of a leptin-signaling related bone 
phenotype is thought to have two potential sources.  The first, and most common, occurs 
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due to alterations in leptin signaling in the brain (Ducy, Amling et al. 2000).  Femur 
length is shortened in both leptin deficient ob/ob and ObRb knockout (KO) db/db mice as 
well as mice with a point mutation in ObRb that prohibits Stat3 signaling which suggests 
an anabolic effect of leptin (Myers personal communications)(Hamrick, Pennington et al. 
2004; Ealey, Fonseca et al. 2006; Scheller, Song et al. 2010).  Femur length deficits of 
leptin-deficient ob/ob mice can be fully corrected after 15 weeks by leptin gene therapy 
in the brain (Iwaniec, Boghossian et al. 2007) and also partially restored by peripheral 
intra-peritoneal (IP) injection of 50µg/day leptin for four weeks (Steppan, Crawford et al. 
2000).  The second possible mechanism of leptin-mediated bone changes occurs when 
leptin acts directly on a peripheral cell such as the MPC to regulate differentiation and 
subsequent bone formation (Scheller, Song et al. 2010). 
 
Generation of a mouse model with floxed ObRb has allowed use of conditional ObRb 
KO mice to determine the relative contributions of the central and peripheral mechanisms 
of leptin regulation on bone formation (McMinn, Liu et al. 2004).  Leptin or ObRb 
deficient mice have decreased femur length that is due to a central depletion of leptin 
signaling.  In contrast, the femur length of our 3.6
Cre+F/F
 mice was increased by 5.4+/-
0.16% in addition to approximately 80% increases in trabecular bone volume fraction and 
bone mineral density (Figure 21).  We hypothesize that this is driven by peripheral 
deletion of leptin receptors on the MPC, but due to the non-specific recombination in 
other tissues can not yet rule out the contribution of central leptin actions.  In this study 
we systematically investigated the ability of both Col2.3-Cre and Col3.6-Cre to drive 
non-specific loxP recombination in the brain.  In addition, to determine the contribution 
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of central leptin signaling to the Col3.6 bone phenotype, we evaluated the ability of leptin 
to force recombination in leptin-responsive P-Stat3 positive neurons.  Lastly, to 
determine if central leptin resistance may be contributing to the obesity of 3.6
Cre+F/F
 
animals, we quantified the ability of leptin to induce phosphorylation of hypothalamic 
Stat3 in 42 week old 3.6
Cre-
 and 3.6
Cre+F/F
 mice.   
 
4.3 Materials and Methods  
Animals 
All procedures were approved by the University Committee on the Use and Care of 
Animals.  Col2.3-Cre and Col3.6-Cre mice were obtained from Dr.Fei Liu (University of 
Michigan) (Liu, Woitge et al. 2004).  ROSA-EGFP mice were obtained from Jackson 
Laboratory (Stock no: 004077).  Col-Cre mice were crossed with ROSA reporter mice 
and three F1 pups per promoter were analyzed at 12-16 weeks of age.  Cre genotyping 
primers: CreF CGCAGAACCTGAAGATGTTCGCGATTA;  CreR 
TCTCCCACCGTCAGTACGTGAGATATC.  3.6
Cre+F/F
 mice were generated as 
described previously (Scheller, Song et al. 2010). 
 
Leptin injection 
Co-localization studies: Mice were anesthetized with isoflurane and a 26 gauge ICV 
cannula was implanted into the lateral ventricle at A/P -0.34, M/L -1.0, D/V -2.4 
(Franklin and Paxinos 1997).  The cannula pedestal was affixed to the skull with surgical 
adhesive, wound closed, and a dummy injector placed for the duration of recovery.  
Recovery lasted for one week with analgesia (Buprenex) prior to and 12h post surgery.  
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Mice were then treated with 3µg leptin (3µL of 1mg/mL Leptin [a generous gift from 
Amylin] injected at a rate of 1 µL per minute).   
Aged 3.6
Cre+F/F
 studies: 42 week old mice were injected intraperitoneally (IP) with 5 
mg/kg leptin.  Two hours post-treatment mice were anesthetized with an overdose of IP 
pentobarbitol and transcardially perfused with 10% normal buffered formalin.   
 
IHC 
Brains were removed, postfixed overnight and dehydrated in a 30% sucrose solution.  
Immunostaining was performed as described previously (Leinninger, Jo et al. 2009).  A 
freezing microtome was used to collect 30µm serial coronal sections, collected in four 
consecutive series.  Brain sections were incubated in rabbit anti-P-STAT3 (1:250, Cell 
Signaling) and chicken anti-GFP (1:1000, AbCam) overnight at room temperature, then 
visualized by using a biotin-conjugated secondary antibody (1:250, Jackson Immuno 
Research) and DAB (Vectastain ABC kit, Thermo Scientific) or secondary 
immunofluorescence using species-specific Alexa-488 or −568 antibodies (1:200, 
Invitrogen).  Stained sections were mounted onto gelatin-coated slides using ProLong 
Gold Antifade reagent (Invitrogen). 
 
Image Analysis and Statistics 
Sections were imaged with NIS-Elements on a Nikon Eclipse E600 and grouped into 
composite images for each brain region to be analyzed.  ImageJ was used to threshold the 
composites and determine the number of positive neurons per unit area in each brain 
region (Abramoff, Magelhaes et al. 2004).  A two-tailed, homoscedastic t test was used to 
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determine significance between control and experimental groups at p<0.050. Values are 
reported as mean ± the standard deviation. 
 
4.4 Results  
Both Col3.6-Cre and Col2.3-Cre induce neural loxP recombination 
Col2.3-Cre and Col3.6-Cre were bred with ROSA-EGFP reporter mice (Scheller, 
Leinninger et al. 2011).  Cre recombinase forces recombination of loxP sites and excision 
of the intervening DNA in tissues that express Col2.3 or 3.6.  Coronal sections of the 
mouse brain were collected and stained, our figure presents representative images from 
four brain regions measured with respect to Bregma (Figure 25).  Deletion of loxP 
removed a stop sequence in front of an enhanced green fluorescent protein (EGFP) locus 
(Figure 26) (Mao, Fujiwara et al. 2001).  Expression of EGFP in the brain of 2.3
ROSA-EGFP
 
and 3.6
ROSA-EGFP
 was analyzed indirectly with an anti-GFP antibody.  Few positive neural 
cells in the 2.3
ROSA-EGFP
 mice were noted with most expression located near the base of 
the brain around the bottom of the third ventricle (3V), including the arcuate nucleus of 
the hypothalamus (Figure 26).  The 3.6
ROSA-EGFP
 mice showed significantly more positive 
cells in regions spanning from the forebrain to the hindbrain centered predominantly 
around the third ventricle (3V), dorsal third ventricle (D3V) and aqueduct (Aq) (Figure 
26).  In the hypothalamus the ventral medial hypothalamus (VMH,*) was specifically 
negative for EGFP
+
 neurons (Figure 26).  
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Col3.6 induces mild co-localization with leptin-responsive neurons  
Injection of leptin IP or directly into the lateral ventricle produced a robust P-Stat3 
response in hypothalamic brain regions including the posterior hypothalamus (PH), 
ventral premammillary nucleus (PMv), arcuate nucleus (Arc), dorsal and ventral medial 
hypothalamus (DMH/VMH), and lateral hypothalamic area (LHA), consistent with 
previous reports (Faouzi, Leshan et al. 2007).  We also examined representative sections 
from one of four series per brain including the ventral tegmental area and pre-optic areas.  
An average of 5-10% of P-Stat3 positive neurons co-localized with EGFP
+
 cells in the 
ARC, VMH, PMv, and LHA (Figure 27).  When repeated with Col2.3 mice, very little 
co-localization was noted (0-1%) with the highest levels present in the arcuate nucleus 
(Figure 28).     
Forebrain Hindbrain
0.5 -1.9 -4.8 -7.8
 
Figure 25.  Diagram of the mouse brain.  Serial frozen sections were harvested through the entire mouse 
brain.  Sections were evenly divided into four groups to generate four representative sets of brain tissue.  
One set was stained and analysed for enhanced green fluorescent protein expression.  Presented images 
represent sections as indicated with dashed lines and are labeled in relation to the landmark Bregma.  Image 
Credit: The Mouse Brain in Stereotaxic Coordinates, 2
nd
 Edition, G Paxinos and K. B. J. Franklin. ©2001 
by Academic Press.  Used with permission.     
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Figure 26.  Ectopic expression of Col2.3 and Col3.6 promoters in the brain.  (A) Col2.3-Cre and Col3.6-
Cre were bred with GFP ROSA reporter mice.  Cre driven recombination of loxP sites (triangles) facilitated 
expression of EGFP. (B) Resulting expression of EGFP in the brain was analyzed.  (C) Col3.6-Cre driven 
neural deletion was nearly absent in the ventral medial hypothalamus.  D3V: dorsal third ventricle, 3V: 
thrid ventricle, Aq: aqueduct, *Ventral Medial Hypothalamus.  Credit: (Scheller, Leinninger et al. 2011) 
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Figure 27.  Co-localization of Col3.6 driven loxP recombination and leptin induced P-Stat3 in the 
hypothalamus.  3.6
ROSA-GFP
 mice were treated with leptin directly into the lateral ventricle of the brain.  
Leptin-responsive P-Stat3 neurons are pictured in red and EGFP positive neurons in green.  Approximately 
5-10% co-localization of P-Stat3 neurons with EGFP was noted in the arcuate nucleus (Arc), dorsal medial 
hypothalamus (DMH), lateral hypothalamic area (LHA), and ventral premammillary nucleus (PMv).  
Credit: (Scheller, Leinninger et al. 2011) 
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Figure 28.  Co-localization of Col2.3 driven loxP recombination and leptin induced P-Stat3 in the 
hypothalamus.  2.3
ROSA-GFP
 mice were treated with leptin directly into the lateral ventricle of the brain.  
Leptin-responsive P-Stat3 neurons are pictured in red and EGFP positive neurons in green.  Approximately 
0-1% co-localization of P-Stat3 neurons with EGFP was noted in the arcuate nucleus (Arc), dorsal medial 
hypothalamus (DMH), lateral hypothalamic area (LHA), and ventral premammillary nucleus (PMv).  
Credit: (Scheller, Leinninger et al. 2011) 
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Aged 3.6
Cre+F/F
 mice have intact, but decreased central leptin response  
The presence of co-localization of P-Stat3 and EGFP
+
 neurons implies that leptin 
signaling may be decreased in the 3.6
Cre+F/F
 mice.  In addition, it has been previously 
reported that obesity enhances leptin resistance (Faouzi, Leshan et al. 2007).  Therefore, 
we examined the combination of ObRb deletion and leptin resistance on the P-Stat3 
response in 42 week old male 3.6
Cre+F/F
 mice.  We found that 3.6
Cre+F/F
 mice had increased 
baseline P-Stat3 staining in regions such as the PMV (Figure 29).  The 3.6
Cre+F/F
 mice 
also had decreased P-Stat3 response to IP-delivered leptin in the LHA, Arc and 
DMH/VMH when compared to controls (Figure 29).  Due to high background P-Stat3 
staining in the arcuate nucleus a significant increase in staining could not be detected 
after leptin addition in either group (Figure 29).  However, there was a significant 
reduction of P-Stat3 positive neurons in the Arc of leptin-treated 3.6
Cre+F/F
 mice when 
compared to controls (Figure 29).  Longitudinal food intake analysis of 24 to 28 week old 
female mice revealed that after 14 days significant differences in chow consumption were 
noted (Figure 29a).  These changes continued to be significant after 28 days, though no 
change in average body mass was noted in the 3.6
Cre-
 or 3.6
Cre+F/F
 animals during that 
time (Figure 29a). 
 
4.5 Discussion  
The first goal of this study was to examine expression of the Col3.6 and Col2.3 
promoters in the brain to determine the potential role for non-specific central ObRb 
deletion in the bone phenotype of the 3.6
Cre+F/F
 mice (Table 6).  We found significant cre-
induced loxP recombination with both promoters, though Col3.6-Cre induced much more 
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widespread deletion that centered on the 3V, D3V, and Aq.  Unanticipated neural 
expression is not unique to these promoters and has also been found with the previously- 
assumed adipose-specific Fabp4-Cre, Jackson Labs stock no:005069 (Heffner and 
Sharma 2010).  These unexpected findings highlight the need to perform full body 
+PBS
+Leptin
Cre- 3.6Cre+F/F
62.3 +/- 4.5a 51.0 +/- 9.9a
1.0 +/- 1.8 10.6 +/- 9.2
Cre-
4.1 +/- 0.52 2.5 +/- 0.5c
2.3 +/- 1.9 2.6 +/- 0.5
Posterior Hypothalamus Arcuate Nucleus
10.8+/-4.6a2.70+/-1.7a,c4.36+/-2.02dCre+ Lep
1.58+/-0.30b0.16+/-0.210.89+/-1.49Cre+ PBS
7.18+/-2.1a7.17+/-3.32a17.0+/-12.2dCre- Lep
0.21+/-0.040.40+/-0.440.04+/-0.07Cre- PBS
PMVLHADMH/VMH
A
B
3.6Cre+F/F
 
Figure 29.  Leptin induces a P-Stat3 response in both control and 3.6
Cre+F/F
 mice.  Fourty-two week old 
mice received intraperitoneal injection of 5mg/kg leptin two hours before perfusion and analysis.  (A) 
Representative images from the posterior hypothalamus and arcuate nucleus.  (B) Additional quantified 
data from hypothalamic brain regions.  N=3.  a: significant over matched PBS; b: significant over control 
PBS; c: significant over control leptin; d: non-significant trend over matched control p<0.100.  Credit: 
(Scheller, Leinninger et al. 2011) 
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Figure 29a.  Longitudinal food intake analysis of 3.6
Cre-
 and 3.6
Cre+F/F
 mice.  Female mice from 24 to 28 
weeks were single housed and provided 90-100g of food per week.  Chow consumption and body mass was 
quantified every seven days.  Bedding was checked for dropped food particles. (A) Total chow 
consumption.  (B) Average body mass.  N=4.  *: significant over matched control.  Credit: E.L. Scheller, 
unpublished data. 
analysis when characterizing tissue-specific transgenic animals.  The further address the 
aim of this study we examined co-localization of neurons lacking ObRb with leptin-
induced P-Stat3 signaling.  Co-localization studies revealed that while Col3.6 was 
expressed widely in the brain, the neurons that were affected only overlapped with leptin-
responsive P-Stat3 neurons in 5-10% of cases.  In the case of Col2.3, co-localization was 
nearly absent.  As previously discussed, complete ObRb KO mice have decreased femur 
length.  It is thus unlikely that removal of 5-10% of central leptin signaling would result 
in the opposite phenotype of increased femur length through a mechanism that involves 
direct sympathetic regulation of osteoblasts or osteoclasts (Ducy, Amling et al. 2000). 
 
The second goal of this study was to determine the potential contribution of central leptin 
signaling to the increased accumulation of peripheral fat observed in our 3.6
Cre+F/F
 mice 
(Figure 18).  Though we believe that the observed 5-10% co-localization is unlikely to 
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drive the observed bone phenotype, it is highly possible that neural modulation of food 
intake is dose dependently related to the number of active leptin receptors in the 
hypothalamus.  Thus, decreasing the ability of leptin to signal through P-Stat3, even by 
only 5-10%, may result in a slight change in food intake and adipose accumulation.  
Development of slight central leptin resistance with age as we also observed may further 
compound this hyperphagia.  However, it should be noted that both 3.6
Cre-
 and 3.6
Cre+F/F
 
animals had similarly high levels of background P-Stat3 in the arcuate nucleus making 
any effect of leptin impossible to determine.  The arcuate nucleus is thought to be the 
main center controlling leptin regulation of food intake (Satoh, Ogawa et al. 1997).  This, 
combined with the modest 5-10% co-localization, may explain why food intake changes 
were only observed longitudinally and not significant enough to be detected upon acute 
analysis. 
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CHAPTER 5 
ZOLEDRONIC ACID INHIBITS MACROPHAGE SOCS3 EXPRESSION AND 
ENHANCES CYTOKINE PRODUCTION  
 
5.1 Summary    
Suppressor of cytokine signaling-3 (SOCS3) has multiple functions including inhibition 
of Janus kinase activity, regulation of protein degradation, and suppression of cytokine 
signaling.  SOCS3 modulates macrophage response to cytokines such as IL-6 and leptin 
that are systemically induced in obesity. Obesity is a suspected risk factor for SOCS3-
related pathology such as rheumatoid arthritis and Crohn’s disease as well as zoledronic 
acid (ZA)-induced osteonecrosis of the jaw (ONJ).  Thus, understanding the ability of 
bisphosphonates to modulate SOCS3 is necessary to qualify their contribution to these 
disorders.  ONJ occurs in up to 10% of patients using intravenous bisphosphonates and 
has an unknown pathogenesis that may be linked to decreased bone turnover, altered 
vascularity, bacterial invasion, and compromised wound healing.  Given the increased 
risk of ONJ with obesity and importance of macrophages in wound healing, we 
hypothesized that amino-bisphosphonates could contribute to the pathogenesis of ONJ by 
regulating macrophage responses to cytokines such as leptin and IL-6.  We report that 
zoledronic acid is a novel inhibitor of SOCS3 in primary macrophages and human ONJ 
biopsy specimens.  Inhibition of SOCS3 by ZA resulted in significant increases in IL-6 
production.  SOCS3 transcription is regulated by nuclear accumulation of 
phosphorylated-Stat3 (P-Stat3).  We found that ZA decreased phosphorylation of Stat3 in 
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a mevalonate-pathway dependent manner.  However, restoration of P-Stat3 was not 
sufficient to correct SOCS3 inhibition.  We propose that disruption of macrophage 
SOCS3 expression by amino-bisphosphonates such as ZA may be a novel contributor to 
inflammatory phenotypes in obesity and the pathogenesis of ONJ. 
 
5.2 Introduction  
Suppressor of Cytokine Signaling-3 (SOCS3), a member of the SOCS family of proteins, 
has multiple domain-specific functions that include inhibition of Janus kinase (Jak) 
activity, competition with signal transducer and activator of transcription (Stat) proteins, 
regulation of protein degradation, and suppression of cytokine signaling (Piessevaux, 
Lavens et al. 2008).  Expression of SOCS3 is induced by extracellular binding proteins 
such as interleukin 6 (IL-6), IL-10, interferon gamma (IFN-y), bacterial 
lipopolysaccharide (LPS), and leptin.  Complete deficiency of SOCS3 in mice is lethal 
due to placental defects (Yasukawa, Ohishi et al. 2003), however, conditional deletion 
has revealed a wide role for SOCS3 in cells and tissues including macrophages (Ohishi, 
Matsumura et al. 2005), the central nervous system (Mori, Hanada et al. 2004), T cells 
(Kinjyo, Inoue et al. 2006), the pancreas (Mori, Shichita et al. 2007), and the liver (Ogata, 
Chinen et al. 2006).  Alterations in SOCS3 protein levels may play a significant role in 
the pathogenesis of inflammatory diseases including rheumatoid arthritis (Isomaki, 
Alanara et al. 2007), inflammatory bowel disease (Suzuki, Hanada et al. 2001), and 
Crohn’s disease (Lovato, Brender et al. 2003).   
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Zoledronic acid (ZA) is a commonly used amino-bisphosphonate medication that is 
approved in the United States for treatment of Paget’s disease, postmenopausal 
osteoporosis, multiple myeloma, and bone metastases from solid tumors (Ibrahim, Scher 
et al. 2003).  Additional off-label uses such as treatment of osteoarthritis and rheumatoid 
arthritis are growing increasingly popular (Jarrett, Conaghan et al. 2006; Zoler 2010).  
ZA is highly potent with a half-life potentially exceeding 10 years and becomes 
incorporated in the bone after initial administration (Khan, Kanis et al. 1997).  The 
compound is then gradually released during bone remodeling.  This generates potential 
for long-term systemic effects and has been linked to complications such as osteonecrosis 
of the jaw (ONJ).  ONJ is diagnosed when a patient with a history of bisphosphonate use 
and without previous radiation treatment presents with exposed bone in the oral cavity 
that fails to heal after eight weeks (Novince, Ward et al. 2009).  A survey of over 700,000 
medical claims revealed that those taking IV bisphosphonates were at a four to six-fold 
increased risk of requiring jaw surgery due to inflammatory changes (Cartsos, Zhu et al. 
2008) and a survey of cancer patients specifically taking ZA found a 30-fold increase in 
risk of ONJ (Wessel, Dodson et al. 2008).   
 
In patients taking ZA, obesity is also a risk factor for development of ONJ (Wessel, 
Dodson et al. 2008).  Obesity has been linked to significant increases in systemic markers 
of inflammation such as c-reactive protein and circulating inflammatory cytokines such 
as leptin, IL-6, and TNF-α (Considine, Sinha et al. 1996; Das 2001; Fontana, Eagon et al. 
2007).  Obesity is also a suspected risk factor for SOCS3-related inflammatory disorders 
such as rheumatoid arthritis and Crohn’s disease (Voigt, Koepsell et al. 1994; Mendall, 
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Gunasekera et al. 2011).  Given the increasing prevalence of amino-bisphosphonate use, 
understanding the ability of these compounds to modulate inflammation and macrophage 
cytokine production is necessary to qualify their contribution to these disorders. 
   
The main function of amino-bisphosphonates such as ZA is to reduce osteoclast activity 
both by induction of osteoclast apoptosis (Sudhoff, Jung et al. 2003) and inhibition of 
osteoclast maturation through blockage of protein prenylation and geranyl-geranylation 
in myeloid precursor cells (Coxon, Helfrich et al. 2000; Russell, Watts et al. 2008).  
Although the macrophage and the osteoclast originate from a common precursor, much 
less is known about the effects of bisphosphonates on macrophage gene expression.  
Macrophages play an important role in the early phase of wound healing.  In addition to 
the phagocytosis of debris and bacteria, macrophages release cytokines that promote 
proliferation of fibroblasts and endothelial cells.  Some studies have suggested that 
reduced macrophage infiltration may, in part, be responsible for the increased rate of 
healing in oral mucosa compared to dermal sites (Szpaderska, Zuckerman et al. 2003).  
We previously demonstrated that macrophages are present in human ONJ biopsy 
specimens with a trend toward increased macrophage numbers in patients with IV 
bisphosphonate-induced ONJ (Scheller, Baldwin et al. 2011).  Thus, understanding the 
mechanisms by which bisphosphonates regulate macrophage functions, such as cytokine 
secretion, may provide insight into the pathogenesis of ONJ and lead to discovery of new 
therapeutic targets.  Given the increased risk of ONJ with obesity and the importance of 
macrophages in wound healing, we hypothesized that amino-bisphosphonates could 
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contribute to the progression of ONJ and other inflammatory disorders by regulating 
macrophage responses to systemic cytokines such as leptin and IL-6.   
 
5.3 Materials and Methods  
Transgenic Mice 
All procedures were approved by the University Committee on the Use and Care of 
Animals.  Mice with the coding sequence for exon17 of the long-form leptin receptor 
(ObRb) flanked by loxP were obtained from Dr. Martin Myers (University of Michigan) 
with permission of Dr. Streamson Chua (Columbia University) (McMinn, Liu et al. 
2004).  Mice with germline transmission of the recombined floxed region and 
inactivation of leptin receptor signaling were used in our study and are referred to as 
knockout (KO) mice.  ObRb transgenic s/s (point mutation at tyrosine 1138) and l/l (point 
mutation at tyrosine 985) mice were the generous gift of Dr. Peter Mancuso (University 
of Michigan) and are also available from Jackson Labs (Stock No. 008518 and 008385).  
Genotyping of s/s, l/l, and ObRb KO mice was performed from tail biopsy as described 
previously (Bates, Stearns et al. 2003; McMinn, Liu et al. 2004; Bjornholm, Munzberg et 
al. 2007).  Recombination and deletion of the loxP flanked allele was determined using a 
three-primer system designed by McMinn et al (McMinn, Liu et al. 2004).   
 
Cell Culture 
Human 
Primary human bone marrow macrophages (hBMMs) were differentiated from primary 
marrow of iliac crest specimens (60 year old male) obtained with University of Michigan 
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Institutional Review Board (IRB) approval.  Fragments were washed extensively with 
PBS and marrow suspension processed with Lympholyte® Mammal gradient cell 
separation media (Cedarlane® Laboratories, Cat:CL5110) to remove dead cells and 
erythrocytes.  Briefly, 4mL cell suspension was layered on 3mL Lympholyte® and 
centrifuged at 800g for 20 minutes at room temperature.  The lymphocyte layer was 
harvested with a Pasteur pipet and washed three times in media.  Cells were plated in 
macrophage growth medium (α-Modified Eagle’s Medium (α-MEM; Invitrogen/Gibco), 
10% FBS (Gibco, Lot no.451459), 100U/ml penicillin, 100mg/ml streptomycin sulfate 
(Gibco Cat:15140)) at a density of 700,000 cells/cm
2
 in 100ng/mL recombinant human 
macrophage colony stimulating factor (M-CSF) (Peprotech, Cat:300-25).  Media was 
replenished after two days.  At day four serum free media ± ZA was added overnight 
before stimulation with 50ng/mL IL-6 (Peprotech, Cat:200-06) for five hours.  
 
Mouse 
Bone marrow macrophages (BMMs) were generated by plating the total marrow from 
two mice (femora, tibiae, and humeri) to 36-wells of two 24-well plates for ELISA or 
five 60mm dishes for Western blot analysis.  Cells were derived in macrophage growth 
medium plus 70ng/mL M-CSF (Peprotech, Cat:315-02)) for 2-3 days.  Primary BMMs 
were serum starved in the presence of ZA ((Novartis, Zometa®) overnight (16-18 hours) 
before treatment with 100nM recombinant mouse leptin (R&D Systems, Cat:398-LP-
01M), 20% fetal bovine serum, or 25ng/mL IL-6 (PeproTech, Cat:216-16) for 1 hour for 
qPCR, 3 hours for Western blot analysis, or 24 hours for ELISA.  Cells were treated with 
 97 
5-10µM trans,trans-Farnesol (FOH) (Sigma:277541) or geranylgeraniol (GGOH) 
(Sigma:G3278) where indicated.    
 
ELISA 
BMMs were plated in 24-well plates, six wells per data point per experiment.  All 
experiments were repeated at least twice.  After three days of BMM differentiation, cells 
were serum starved in the presence of 10
-7
 to 10
-5
M ZA overnight.  Subsequently, 250uL 
of α-MEM + 0.5% BSA (Sigma, Cat:A8806) containing fresh ZA and 100nM Leptin as 
added as indicated.  Supernatant was harvested after 24 hours and stored at -80
o
C until 
analyzed.  Post-supernatant removal, genomic DNA was harvested using the QIAGEN 
DNeasy kit (Cat:69506) by adding PBS, proteases, and buffer directly to each well 
followed by incubation of the whole plate at 55
o
C.  Harvested DNA was quantified using 
a UV spectrophotometer at 260nm.  Ratio of 260nm to 280nm absorbance was greater 
than 1.4 for sample acceptance.  Ten to twenty-five microliters of supernatant was 
analyzed with an IL-6 ELISA kit (R&D Systems, Cat:M6000B).  Results from each well 
were normalized to total genomic DNA.   
 
Western Blot Analysis 
Protein was harvested using NP-40 lysis buffer (10% glycerol, 1% NP-40, 50mM Tris pH 
7.4, 200mM NaCl, 2mM MgCl2, 1mM PMSF, 1xProtease Inhibitor Cocktail (Sigma 
Cat:P8340)).  Cells were collected and pelleted in 1mL ice cold PBS at 4
o
C.  Cell pellets 
were resuspended in 25-50µL of lysis buffer, incubated for 30min on ice, centrifuged at 
13,000rpm for 10 minutes, and supernatant harvested.  Protein concentration was 
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measured at 595nm with Bio-Rad protein assay dye concentrate (Cat:500-0006).  Protein 
extracts (30-80µg) were boiled in 2x SDS sample buffer 5min and separated on a 12% 
Tris-HCl polyacrylamide gel (Bio-Rad).  Protein was transferred to PVDF membranes 
using a wet transfer system (Bio-Rad Cat:170-3930).  Membranes were blocked in 5% 
milk (Stat3, P-Stat3, GAPDH; Bio-Rad, Cat:170-6404) or 5% BSA (SOCS3, Sigma, 
Cat:A7906) one hour and probed overnight with 1:1000 P-Stat3 (Cell Signaling:9131) or 
1:1000 SOCS3 (Cell Signaling:2923) and stripped and re-probed the next day with 
1:1000 Stat3 (Cell Signaling:9132) and/or 1:1000 GAPDH (Chemicon® 
International:MAB374). Signals were amplified with 1:3000 HRP-conjugated secondary 
antibody (Santa Cruz Biotechnology) and SuperSignal® West Pico Chemiluminescent 
Substrate (Thermo Scientific, Pierce Product) and developed using film exposure. 
 
Human Tissue Collection 
Biopsies were accessioned with University of Michigan IRB approval.  Biopsies were 
identified as described previously (Scheller, Baldwin et al. 2011) and assigned to one of 
two groups, no BP history (control) or ONJ.  H&E stained slides of all cases were 
examined to ensure that each specimen contained epithelium and connective tissue. 
Histological identification of non-vital bone with associated bacterial colonies, consistent 
with osteonecrosis, was also required. 
 
Immunofluorescence 
Cells were fixed for 5 minutes in methanol at -20
o
C before PBS wash and 
permeabilization with 1% Triton-X-100 in PBS.  Cells were blocked in PBS+2.5% goat 
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serum+2.5% donkey serum+0.1% Triton-X-100 for 30 minutes.  CD68 primary antibody 
(1:500, AbCam:ab955) was added in 1:10 diluted block for one hour and after washing 
signal was amplified with secondary antibody (1:500 Donkey anti-mouse Cy
TM
3, Jackson 
ImmunoResearch) for 45 minutes.  Nucleic acids were visualized with DAPI. 
 
Immunohistochemistry 
Immunohistochemistry was performed as described previously (Scheller, Baldwin et al. 
2011).  Formalin-fixed sections were deparaffinized in xylene and rehydrated.  Antigen 
retrieval was performed in pH 6.0 citrate buffer.  Endogenous peroxidase was quenched 
in 3% hydrogen peroxide for 30 minutes followed by permeabilization in 0.1% Triton-X-
100 in PBS.  Slides were blocked with 2.5% normal horse serum.  Primary antibodies 
were added overnight at 4
o
C: CD68 (1:500, Abcam:ab955) and SOCS3 (1:500, 
Abcam:ab16030).  Signal was amplified with ImmPRESS reagent (VectorLabs:MP-
7500) and imaged with ImmPACT DAB substrate (VectorLabs:SK-4105).  Slides were 
counterstained with hematoxylin.  Serial sections were stained for CD68 and SOCS3.  
Comparison was performed by generating a representative image composite of all CD68 
or SOCS3 stained sections to ensure identical analysis of all images (40x magnification), 
images were then processed with Adobe Photoshop CS3 by using selectcolor 
rangereds to remove background blue hematoxylin staining.  The resulting composite 
was thresholded with ImageJ (Scion Corp., Frederick, MD, USA) and total pixel density 
of stain per total field size of each specimen recorded.  Results are expressed as the ratio 
of SOCS3 stain density to CD68 stain density in percent.      
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PCR   
Total RNA was extracted from primary BMMs using TRIzol reagent (Invitrogen). Total 
RNA (0.6µg) was converted to cDNA using the SuperScript® III First-Strand Synthesis 
SuperMix Kit (Invitrogen:11752).  Resulting cDNA was diluted 1:20 and used for 20µL 
reactions in SYBR® Green PCR master mix (Applied Biosystems).  PCR and 
determination of the computed threshold was performed on an iCycler (Bio-Rad).  
SOCS3 primers based on sequence NM_007707 are as follows: 
Right_AACTTGCTGTGGGTGACCAT, Left_ AAGGCCGGAGATTTCGCT. 
  
Statistical Analysis 
A two-tailed, homoscedastic t test was used to calculate statistical differences between 
control and experimental groups. Values are reported as the mean
 
± the standard 
deviation.  P<0.050 was considered statistically significant.  For western blot, band 
density was measured with UVP® VisionWorksLS
TM
 image acquisition and analysis 
software.  For Figure 2 and 3, SOCS3 band density was normalized to GAPDH band 
density.  For Figure 3, P-Stat3 band density was normalized to Stat3 band density.  The 
resulting value was then normalized to GAPDH.  To evaluate significance, the control 
ratio of [(P-Stat3/Stat3)/GAPDH] for each time point was set to 1.0.  The value from the 
corresponding ZA treated time point was then assigned a proportional fraction of 1.0.  
This fraction was then compared between multiple independent blots, three to five blots 
per time point, and statistics calculated as above.   
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5.4 Results  
Zoledronic Acid enhances leptin-induced IL-6 production in an ObRb Tyr985-
dependent manner 
Primary bone marrow macrophages (BMMs) from control and complete long-form leptin 
receptor (ObRb) knockout (KO) mice were stimulated with 100nM leptin and 10
-7
 to 10
-
5
M zoledronic acid (ZA) (Figure 30).  The conditioned medium was subsequently 
analyzed for IL-6 and normalized to total genomic DNA per well.  ZA alone induced a 
1.68 fold (p=0.006) increase of IL-6 in control cells and a 2.44 fold (p<0.001) increase in 
KO cells (Figure 30).  Administration of 100nM leptin induced a leptin-specific 2.01 fold 
(p<0.001) increase of IL-6 in control cells with no change in ObRb KO cells confirming 
the ability of leptin to induce IL-6 through ObRb (Figure 30).  Combination treatment 
with 10
-5
M ZA and 100nM leptin produced a synergistic 5.78 fold (p<0.001) increase in 
IL-6 above that induced by ZA or leptin alone (Figure 30).  This synergy was not 
observed in the KO cells (Figure 30).   
 
To determine which signaling pathway was responsible for the increased cytokine 
production with combined leptin and ZA treatment, we utilized two mouse models with 
gene targeted deletions in the signaling components of the leptin receptor, ObRb.  ObRb 
has two signaling phosphotyrosines, Tyr1138 and Tyr985, on the cytoplasmic domain of 
the receptor.  Point mutation of Tyr1138, which was generated in s/s gene targeted mice, 
blocks leptin signaling through P-Stat3 and SOCS3.  In contrast, mutation of Tyr985 of 
the leptin receptor in l/l mice blocks 70-100% of downstream Erk signaling (Myers 
2004).  The signaling deficits of s/s and l/l mice have been previously verified in the 
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Figure 30.  Zoledronic acid and leptin induce synergistic IL-6 production.  (A) Genomic DNA PCR 
confirming complete cre-lox recombination of the bone marrow macrophages from the long-form leptin-
receptor (ObRb) knockout (KO) animals and intact ObRb in the controls.  (B) IL-6 ELISA of control and 
KO BMMs after 16-18 hour pretreatment with ZA followed by induction with 100nM leptin for 24 hours.  
N=6.  *: significant over NT control, **: significant over ZA only control.  Credit: (Scheller, Hankenson et 
al. 2011)   
central nervous system (Bates, Stearns et al. 2003; Bjornholm, Munzberg et al. 2007) and 
in peripheral macrophages (Mancuso, Peters-Golden et al. 2011).  BMMs harvested from 
s/s and l/l mice were genotyped (Figure 31) and treated as described above.  Repetition of 
the ELISA experiment revealed a 16.87 fold (p=0.001) synergistic increase in IL-6 after 
combined leptin and 10
-5
M ZA treatment in the s/s BMMs but not in the l/l BMMs 
(Figure 31).  This implies that synergistic induction of IL-6 production by Leptin and ZA 
requires Tyr985-directed Erk signaling. 
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Figure 31.  Leptin-induced IL-6 production is mediated by ObRb tyrosine 985.  (A) Confirmatory 
genotyping of s/s (point mutation ObRb Tyr1138) and l/l (point mutation ObRb Tyr985) mice.  (B) IL-6 
ELISA of s/s and l/l bone marrow macrophages after 16-18 hour pretreatment with zoledronic acid (ZA) 
followed by induction with 100nM leptin for 24 hours.  N=6.  *: significant over NT control, **: significant 
over ZA only control.  Credit: (Scheller, Hankenson et al. 2011) 
ZA blocks SOCS3 protein accumulation by BMMs 
The s/s transgenic mice that lack the ability to signal through P-Stat3 and SOCS3 
demonstrated a robust synergistic increase in macrophage IL-6 output.  A similar increase 
was observed after treatment of control macrophages with leptin and 10
-5
M ZA.  Since 
SOCS3 is a known inhibitor of leptin signaling, we hypothesized that ZA may be 
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regulating cellular SOCS3 accumulation.  SOCS3 is a negative-feedback regulator of 
signaling molecules such as leptin and IL-6, and induction of SOCS3 expression can 
decrease macrophage cytokine production (Yoshimura, Naka et al. 2007).  We found that 
stimulation of BMMs with 20% FBS for three hours increased SOCS3 protein 1.8-fold 
(Figure 32).  Treatment with 10
-6
M or 10
-5
M ZA inhibited this increase in a dose 
dependent manner.  Leptin induction of SOCS3 protein levels by 2.4-fold at three hours 
was also inhibited dose dependently by 10
-6
 or 10
-5
M ZA (Figure 32).  Similarly, SOCS3 
inhibition after stimulation with 25ng/mL IL-6 by ZA was noted (Figure 32).     
 
ZA reduces phosphorylation of Stat3 in a mevalonate-pathway dependent manner 
Since SOCS3 RNA is induced by nuclear accumulation of P-Stat3 and previous reports 
have suggested that ZA can modulate P-Stat3 levels in clonal macrophages (Reuben, 
Dinh et al. 2011), we investigated the ability of ZA to regulate P-Stat3 in primary BMMs. 
Addition of 25ng/mL IL-6 for 0 to 180 minutes increased phosphorylation of Stat3 from 
5-30 minutes and again from 120-180 minutes (Figure 33).  Pre-treatment with 10
-5
M ZA 
for 16-18 hours resulted in both an increase in total Stat3 at all time points and a 
reduction in Stat3 phosphorylation (Figure 33).  This approximately 50% reduction in the 
ratio of P-Stat3 to Stat3, normalized to GAPDH, was statistically significant from 5 to 15 
minutes (Figure 33).  Many of the functions of amino-bisphosphonates are mediated by 
their ability to inhibit the mevalonate pathway.  Therefore, mevalonate pathway 
intermediates GGOH and FOH were added to determine the extent to which specific 
intermediates may rescue the bisphosphonate-induced P-Stat3 defect.  Addition of 10µM 
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GGOH did not alter phosphorylation of Stat3.  In contrast, the addition of 10µM FOH 
fully restored levels of P-Stat3 in the presence of 10
-5
M ZA (Figure 34).   
 
B
A
C
SOCS3/GAPDH         1.0          1.8          1.9         1.0   0.6 
Control Mac + IL-6 + ZA
SOCS3
GAPDH
NT         0M        10-7M      10-6M       10-5M
Control Mac + Serum + ZA
NT         0M        10-7M      10-6M       10-5M
SOCS3
GAPDH
SOCS3/GAPDH       1.0          53.9         40.7         16.0   24.0
Control Mac + Leptin + ZA
NT          0M         10-7M      10-6M     10-5M
SOCS3
GAPDH
SOCS3/GAPDH         1.0          2.4           2.6          0.8 0.2 
 
Figure 32.  Zoledronic acid (ZA) inhibits SOCS3 protein accumulation in primary bone marrow 
macrophages.  Western blot densitometry data was normalized to GAPDH control. (A,B,C) ZA 
pretreatment for 16-18 hours from 10
-7
 to 10
-5
M dose-dependently inhibited induction of SOCS3 in BMMs 
by 20% serum, 100nM leptin, or 25ng/mL IL-6 respectively after three hours.  Representative blots shown, 
all experiments repeated at least twice.  Credit: (Scheller, Hankenson et al. 2011)    
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Figure 33.  Zoledronic acid (ZA) inhibits Stat3 phosphorylation.  (A) Control western blot of P-Stat3, 
Stat3, and GAPDH after bone marrow macrophage stimulation with 25ng/mL IL-6 for 0 to 180 minutes.  
(B) Paired western blot after treatment with 10
-5
M ZA.  (C) Statistical analysis of the ratio of 
phosphorylation of Stat3 after ZA treatment to control at each time point.  Control densitometry ratio [(P-
Stat3/Stat3)/GAPDH] was set to 1.0 and corresponding ZA treated ratio given a proportional value before 
statistical comparison of independent blots.  N=3.  Credit: (Scheller, Hankenson et al. 2011)   
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Figure 34.  Farnesyl intermediates rescue zoledronic acid (ZA) mediated inhibition of P-Stat3 and SOCS3 
mRNA.  (A) Western blot of bone marrow macrophages pre-treated with 10
-5
M ZA and 10µM GGOH or 
FOH overnight, ‘-‘ indicates lack of ZA treatment.  Pre-treated cells were stimulated with 25ng/mL IL-6 
for 10-15 minutes.  Tabulated results report the ratio of phosphorylation of Stat3 after ZA treatment to 
control at each time point as in figure 33.  N=3.  (B) Quantitative PCR analysis of SOCS3 mRNA after one 
hour, treatments as above.  Results are reported as percent of control SOCS3 mRNA.  N=3-5.  *: 
significantly less than control.  Credit: (Scheller, Hankenson et al. 2011) 
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Correction of P-Stat3 signaling is not sufficient to rescue SOCS3 protein inhibition   
P-Stat3 nuclear accumulation induces SOCS3 mRNA transcription (Banks, Davis et al. 
2000).  Therefore, we sought to determine if cytokine treatment had a similar effect in 
our system.  Addition of 25ng/mL IL-6 significantly induced SOCS3 mRNA 
accumulation after one hour.  This increase was significantly blunted by treatment with 
10
-5
M ZA and rescued by concomitant treatment with 10µM FOH, but not 10µM GGOH 
(Figure 34).  Despite the complete rescue of P-Stat3 protein and SOCS3 mRNA levels, 
FOH at 5µM or 10µM was not sufficient to rescue SOCS3 protein production (Figure 
35).   
NT         0M      10-7M     10-6M     10-5M       5         10           5        10
Control Mac + IL-6 + ZA +GGOH +FOH
SOCS3
GAPDH
SOCS3/GAPDH    1.0        53.9      40.7       16.0      24.0   10.4      3.1        17.5     13.3
 
Figure 35.  Rescue of P-Stat3 and SOCS3 mRNA with FOH does not correct SOCS3 protein inhibition.  
Representative western blot of SOCS3 after ZA/GGOH/FOH overnight pre-treatment where indicated and 
three hour 25ng/mL IL-6 stimulation of bone marrow macrophages.  GGOH and FOH concentrations are 
reported as µM and combined with 10
-5
M zoledronic acid.  Experiment was repeated three times with 
similar results.  Credit: (Scheller, Hankenson et al. 2011)    
Macrophage-associated SOCS3 levels are decreased in human specimens  
To determine if alterations in SOCS3 were present in human cells and tissue, we 
analyzed both primary human macrophages and ONJ biopsy specimens (Scheller, 
Hankenson et al. 2011).  Human bone marrow macrophages (hBMMs) were harvested 
from iliac crest bone marrow of a 60 year old male donor.  Harvested cells were strongly 
positive for CD68, a macrophage marker, when analyzed with immunofluorescence 
(Figure 36).  SOCS3 protein accumulation induced after five hours of 50ng/mL IL-6 
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treatment was inhibited by pre-incubation of the cells with 10
-5
M ZA (Figure 36) similar 
to studies with mouse BMMs (Figure 32).  Immunohistochemistry for SOCS3 and CD68 
was performed on serial sections of biopsies derived from control human oral ulcerations 
or ulcerations associated with ONJ (Table 8).  Comparison of SOCS3 staining density in 
the areas of macrophage infiltration revealed a significant decrease in SOCS3 in the ONJ 
specimens (16.8±16.2%, p=001) when compared to controls (70.5±27.1%) (Figure 36).   
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Figure 36.  Bisphosphonates decrease SOCS3 in human CD68+ macrophages and human ONJ biopsies.  
(A) Cellular immunofluorescence of primary human macrophages. Red = CD68, Blue = Dapi.  40x 
magnification.  (B) Representative western blot of primary macrophage SOCS3 after treatment with 
50ng/mL IL-6 alone or IL-6 + 10
-5
M zoledronic acid.  Experiment was performed in duplicate with similar 
results.  (C) Representative serially stained sections of control ulcerated tissue and an ONJ lesion.  40x 
magnification.  Credit: (Scheller, Hankenson et al. 2011) 
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Patient Group Age Gender Specimen Diagnosis Bisphosphonate SOCS3 (%) Avg+/-SD (%) P Value
1 Control 57 M Nonspecific Ulcer 100.0 70.5+/-27.1 0.001
2 Control 65 M Traumatic Ulcer 60.2
3 Control 78 M Traumatic Ulcer 41.4
4 Control 81 M Bony Sequestrum 100.0
5 Control 54 F Granulomatous Reaction 40.8
6 Control 65 M Bony Sequestrum 80.5
1 IV BP 65 M ONJ Zometa® 14.4 16.8+/-16.2
2 IV BP 67 F ONJ Zometa® 17.2
3 IV BP 55 F ONJ Zometa® 5.0
4 IV BP 82 M ONJ Zometa® 45.0
5 BP NOS 81 F ONJ Unknown 3.6
6 Oral BP 88 F ONJ Fosamax® 31.4
7 Oral BP 67 F ONJ Fosamax® 1.1  
Table 8.  Patient information, condition, treatment, and SOCS3 percent staining density of human specimens.  Credit: (Scheller, Hankenson et al. 2011) 
 
 
 
 
1
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5.5 Discussion  
SOCS3 is an essential regulator of diverse cellular functions including cytokine 
production and has been implicated in the pathogenesis of inflammatory pathology such 
as Crohn’s disease and rheumatoid arthritis.  We found that the amino-bisphosphonate 
zoledronic acid has the potential to enhance macrophage cytokine secretion by inhibiting 
SOCS3 protein accumulation.  Due to the extended half-life of bisphosphonates and their 
ability to incorporate into the bone matrix (Kozloff, Volakis et al. 2010), it is possible 
that long-term systemic persistence of these drugs may contribute to inflammatory 
pathologic processes through the inhibition of SOCS3.   
 
Indeed, ONJ, an increasingly recognized complication of amino-bisphosphonate 
treatment, may be linked to altered macrophage SOCS3 activity, as preliminary evidence 
suggests that SOCS3 protein levels are decreased in ONJ biopsy specimens when 
compared to controls.  However, it is important to recognize a limitation of this study.  
Except for specimen number five that contained a granulomatous reaction, both the 
controls and the ONJ biopsy specimens represented clinical ulcerations of similar 
appearance.  In all specimens one would expect to see an inflammatory reaction including 
induction of SOCS3.  However, the duration of the ulcers is unknown and their status as 
acute vs chronic inflammatory lesions may also influence SOCS3 protein levels.  Despite 
this level of information, the approximately four-fold decrease in SOCS3 protein levels in 
the ONJ specimens suggests that further investigation in this area may provide additional 
insights on the mechanisms responsible for ONJ.   
 
 112 
The pathogenesis of ONJ is currently unknown but may be linked to decreased bone 
turnover, altered vascularity, bacterial invasion, and compromised wound healing 
(Novince, Ward et al. 2009).  Osteoimmunology is an emerging field of research that 
views regulation of bone metabolism within the context of immune function (Lorenzo, 
Horowitz et al. 2008).  While the macrophage has long been appreciated as a key 
component of the immune system, an essential role for macrophages in bone homeostasis 
was only recently confirmed when induced depletion of macrophages in a mouse model 
ablated mature osteoblast bone-forming surface (Chang, Raggatt et al. 2008).  In addition 
to regulation of osteogenesis, macrophage-released cytokines are regulators of fibroblast 
and endothelial cell proliferation and studies have speculated that reduced macrophage 
infiltration may, in part, be responsible for increased rates of healing of oral mucosa 
compared to keratinized dermal sites (Szpaderska, Zuckerman et al. 2003).  Thus, 
dysregulation of critical macrophage functions such as cytokine production may 
contribute to altered bone remodeling and decreased healing potential observed at sites of 
ONJ.   
 
We found that zoledronic acid at concentrations of 10
-6
 to 10
-5
M is a novel inhibitor of 
serum and cytokine-induced SOCS3 in macrophages in vitro.  Inhibition of SOCS3 was 
also observed in human ONJ biopsy specimens in vivo.  SOCS3 is a potent regulator of 
macrophage responses to systemic cytokines such as IL-6 and leptin that are upregulated 
in states of obesity.  Analysis of alendronate release kinetics in rat bone have 
demonstrated local bisphosphonate concentrations of 10
-3
 to 10
-4
M at sites of active 
resorption after 0.4mg/kg treatment (Sato, Grasser et al. 1991).  In addition, secreted 
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concentrations of 10
-5
M ZA are readily achieved with ZA-loaded bone cement that has 
been proposed for local treatment of giant cell tumor and multiple myeloma (Zwolak, 
Manivel et al. 2010).  This study reveals that the future use of such devices must consider 
complications due to inhibition of SOCS3 and enhancement of a destructive 
inflammatory response.  Though our study has focused on SOCS3 inhibition in the 
context of ONJ, this may also play important roles in other inflammatory conditions such 
as rheumatoid arthritis (Isomaki, Alanara et al. 2007), inflammatory bowel disease 
(Suzuki, Hanada et al. 2001), and Crohn’s disease (Lovato, Brender et al. 2003).   
 
In summary, we conclude that ZA is a novel inhibitor of SOCS3 protein accumulation in 
macrophages, essentially ‘inhibiting the inhibitor’ of signaling by molecules such as 
leptin and IL-6 (Figure 37).  Functionally, administration of ZA with leptin promoted a 
synergistic induction of downstream IL-6 production by primary BMMs that was not 
present in BMMs lacking the long-form leptin receptor (ObRb).  This effect was 
dependent on ObRb tyrosine 985, likely mediated by the downstream Erk pathway 
(Figure 37).  Though ZA was found to decrease both phosphorylation of Stat3 and initial 
induction of SOCS3 mRNA in a mevalonate-pathway dependent manner, rescue of these 
defects with FOH was not sufficient to restore SOCS3 protein levels.  Thus, the specific 
mechanism of SOCS3 inhibition is unclear at this point but may involve a post-
transcriptional process.  Though this study focused on SOCS3 induction by obesity-
related cytokines leptin and IL-6, our results suggest wider implications for regulation of 
additional SOCS3 dependent signaling molecules such as IL-10, LPS and IFN-γ.  In 
conclusion, we propose that inhibition of SOCS3 and dysregulation of macrophage 
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cytokine output may contribute to obesity-associated inflammatory disorders and 
potentially the pathogenesis of ZA-induced ONJ.  
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Figure 37.  Theoretical model of zoledronic acid (ZA) regulation of SOCS3.  ZA taken up by the cell 
blocks phosphorylation of Stat3 in a farnesylation-dependent manner.  ZA, via a secondary mechanism that 
may involve inhibition of protein translation, blocks protein accumulation of SOCS3.  Functionally, this 
results in increased cytokine output of leptin-induced IL-6 in an ObRb Tyr985, Erk signaling dependent 
manner.  Credit: (Scheller, Hankenson et al. 2011)   
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CHAPTER 6 
PROSPECTUS AND CONCLUSIONS 
 
6.1 Further consideration of the 3.6
Cre+F/F
 phenotype 
Investigation of peripheral obesity 
The 3.6
Cre+F/F
 mice presented with an unexpected increase in body mass that was 
primarily attributed to the higher fat content of the transgenic mice (Figure 19).  This 
could be explained by alterations in adipose progenitor cell differentiation, central 
changes in food intake, and/or altered regulation of adipocyte hypertrophy.  We found 
that the Col3.6 promoter was capable of driving loxP recombination in peripheral adipose 
depots, likely due to recombination in an adipocyte precursor cell such as the MPC or 
adipose stem cell (ASC) (Figure 23).  The realization that adipose tissue is a rich source 
of precursor cells has progressed since the late 19th century and in recent years has 
consisted of a switch in nomenclature from “adipocyte precursor” to “adipose stem cell” 
when it was realized that cells within the stromal vascular fraction (SVF) of adipose 
tissue could differentiate into cells other than adipocytes.   
 
Fractionation of adipose tissue as performed in our study consists of collagenase 
digestion and centrifugation to separate floating, lipid-laden adipocytes from a pellet 
referred to as the SVF (Rodbell 1964).  In 1973 growth of fibroblast-like cells from the 
SVF was reported in vitro (Poznanski, Waheed et al. 1973) followed by confirmatory 
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reports of their ability to serve as an adipocyte precursor (Van, Bayliss et al. 1976).  
Despite recognition of this adipocyte precursor in 1976 and appearance of the stem cell 
concept as early as 1909 (Maximow 2009), these two findings were not merged until 
2001 in the first report of a unique, multipotent adipose stem cell (Zuk, Zhu et al. 2001).   
 
At first inspection it appears that ASCs are a subset of the larger class of so-called 
mesenchymal stem cells and share many similarites with MSCs of other tissues.  In vitro 
clonal expansion of single cell preparations of tissues such as bone marrow, synovium, 
adipose, or dental pulp reveals stromovascular progenitor cells (SVCs) capable of 
multilineage in vitro differentiation toward adipocytes, osteoblasts, and chondroblasts 
(Friedenstein, Chailakhjan et al. 1970; Poznanski, Waheed et al. 1973; Gronthos, 
Mankani et al. 2000; De Bari, Dell'Accio et al. 2001).  The ability to form these tissues in 
vivo varies.  Origin of adipose lineages is thought to occur from both the mesoderm and 
the neural crest during development (Billon, Iannarelli et al. 2007).  This dual origin is 
similar to that of bone which derives from neuroectoderm (craniofacial skeleton) and 
axial and lateral specifications of mesoderm (Olsen, Reginato et al. 2000).  However, 
despite definition of an early, transient MSC-like population of neuroectoderm 
(Takashima, Era et al. 2007), adult progenitors appear to have a unique origin that is not 
yet defined.  The subtle differences between SVC populations may represent a similar 
cell of origin that was epigenetically programmed once within its tissue of residence 
(Boquest, Noer et al. 2006).  This epigenetic silencing of certain promoters may explain 
the enhanced ability of the adipose SVC to differentiate toward fat (Boquest, Noer et al. 
2006), in vivo dentin formation by dental pulp SVCs (Shi and Gronthos 2003), enhanced 
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chondrogensis of synovial SVCs (De Bari, Dell'Accio et al. 2001), or the greater 
hematopoetic supportive capacity of the bone marrow SVC (Casteilla, Planat-Benard et 
al. 2011).  If the Col3.6 promoter is able to drive recombination in precursor cells from 
diverse tissues including bone and adipose, this may point to a common origin of these 
cells and provide significant developmental insight.     
 
In support of the contribution of adipocyte hyperplasia to the obesity of Col3.6
Cre+F/F
 
mice, we demonstrated that SVC lacking ObRb isolated from both the bone marrow and 
peripheral adipose tissue could differentiate more robustly to adipocytes in vitro (Figure 
14, Figure 23).  This finding has never been replicated in vivo, and thus the contribution 
of this mechanism to peripheral fat pad size remains unknown.  In addition to increases in 
food intake driving obesity, specific knock-down of ObRb using siRNA in the white 
adipose tissue of mice also results in increased body mass suggesting that leptin 
regulation of fat depot size is regulated peripherally as well as centrally (Huan, Li et al. 
2003).  To further evaluate differentiation in vivo, it would be interesting to cross an 
ObRb null adipose SVC from our 3.6
Cre+F/F
 animals with a PPARγ linked LacZ reporter 
cell (Tang, Zeve et al. 2008).  These cells could then be implanted into adipose depots in 
vivo in wild type mice fed a high fat diet as described previously (Rodeheffer, Birsoy et 
al. 2008) and the contribution of implanted cells compared to ObRb-replete LacZ-
expressing controls.  We would hypothesize that the SVCs lacking ObRb could generate 
increased numbers of adipocytes in vivo in the presence of excess food intake due to the 
lack of leptin differentiation inhibition.      
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In addition to effects on precursor cell differentiation, understanding the accumulation of 
fat in 3.6
Cre+F/F
 mice requires analysis of central regulation of food intake.  We explored 
the metabolic phenotype of the animals using CLAMS.  We also measured the ability of 
leptin to signal centrally through the hypothalamus.  CLAMS metabolic analysis failed to 
reveal any change in spontaneous activity or acute food intake that could explain the 
peripheral obesity (Figure 20).  However, during central analysis, we found that the 
Col3.6 promoter drove non-specific loxP recombination in 5-10% of hypothalamic 
leptin-responsive neurons (Figure 27).  Though it is unlikely that this is directly 
responsible for the observed bone phenotype, it is highly possible that elimination of a 
small proportion of leptin-responsive neurons could result in a proportional increase in 
food intake.  Acute analysis of food intake failed to reveal any differences (Figure 20), 
however, a longitudinal study of mice from 24 to 28 weeks of age revealed an 
approximately 16% increase in chow consumption (Figure 29a).  It is unknown if this 
increase is sufficient to cause and/or maintain the average 63% increase in body mass of 
these same animals.  Paired food provision during development may lead to a resolution 
of this question.  
 
In addition to evidence for adipocyte hyperplasia, the contribution of adipocyte 
hypertrophy to the obesity of the 3.6
Cre+F/F
 mice could be determined.  In complete leptin 
deficient ob/ob mice the rate of lipogenesis in liver and adipose tissue is twice that of 
controls and an increase in adipocyte size is observed at two weeks of age (Coleman 
1978).  As previously mentioned, specific knock-down of ObRb in the white adipose of 
mice in vivo results in increased body mass in the absence of central alteration (Huan, Li 
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et al. 2003).  This may represent changes in both differentiation of adipose precursors or 
modulation of properties of mature adipocytes.  Glucose and insulin have been shown to 
stimulate leptin production by mature adipocytes in vitro, while inhibitors of glycolysis 
induce dose dependent inhibition of secretion (Mueller, Gregoire et al. 1998).  However, 
even at high concentrations (200-2000ng/mL), leptin is not able to modulate basal or 
insulin-stimulated glucose metabolism of either freshly isolated or cultured adipocytes 
(Mick, Vanderbloomer et al. 1998).  Thus, leptin modulation of adipocyte hypertrophy 
may occur through central mechanisms.  Quantification of adipocyte size as well as the 
central and peripheral contribution of leptin to lipogenesis may further explain the obesity 
of 3.6
Cre+F/F
 mice.      
 
Contribution of obesity to the bone phenotype 
It has been established in mice that increases in body mass increase femoral cortical bone 
parameters independent of leptin signaling (Iwaniec, Dube et al. 2009).  This increase in 
cortical bone parameters was accompanied by an increase in femur length (Iwaniec, Dube 
et al. 2009).  Conversely, caloric restriction in mice decreases femoral cortical bone 
mineral content and thickness without changes in femur length (Hamrick, Ding et al. 
2008).  In both instances, either males fed a high fat diet from 16-24 weeks or subject to 
calorie restriction from 14-24 weeks, femoral trabecular bone volume fraction remained 
unchanged (Hamrick, Ding et al. 2008; Iwaniec, Dube et al. 2009).  The mass increase of 
our 3.6
Cre+F/F
 animals is comparable to that observed in animals fed a high fat diet.  Thus, 
it is likely that our observed changes in femoral length and increases in cortical 
parameters at 12 weeks and 42 weeks are related to this change.  However, the observed 
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40-70% increases in trabecular bone volume and bone mineral content can not be 
explained by changes in body weight and are thus assumed to be linked directly to 
alterations in leptin signaling.       
 
Leptin and Chondrogenesis 
Though it appears that increases in body mass of the 3.6
Cre+F/F
 animals may be 
responsible for the increased femur length, the appearance of a bone length phenotype 
warrants discussion of the ability of leptin to regulate chondrogenesis.  In ob/ob mice the 
cartilaginous growth plates have disturbed columnar structure, decreased type X collagen 
expression, increased apoptosis, and premature mineralization (Kishida, Hirao et al. 
2005).  In addition, in vitro matrix mineralization of ob/ob chondrocytes is higher than 
that of wild-type mice (Kishida, Hirao et al. 2005).  These observations are similar to our 
findings with primary ob/ob and db/db BMSCs (Scheller, Song et al. 2010).  Thus, it 
appears that leptin may regulate terminal differentiation of chondrocytes and play a role 
in endochondral ossification at the growth plate.  Since the chondrocyte, osteoblast, and 
adipocyte are derived from a common mesenchymal progenitor it is possible that ObRb is 
not present on chondrocytes in the 3.6
Cre+F/F
 mice.  If true, precise determination of the 
cause of the bone length increase would require independent evaluation of the 
contribution of body mass and leptin-related alterations in endochondral ossification.  
 
6.2 Potential use of recombinant leptin to treat human disease  
Exploring the diverse roles of adipose and leptin signaling in the marrow could provide 
clues to understanding bone metabolism and obesity linked inflammatory disorders such 
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as rheumatoid arthritis, Crohn’s disease, and osteonecrosis of the jaw.  Further 
application of this knowledge to the regeneration of the marrow-supporting osseous and 
cartilaginous structures is a primary goal of the field of bone tissue engineering.  In 
addition to previously published central mechanisms (Ducy, Amling et al. 2000), we have 
explored the ability of leptin to modulate bone formation through peripheral cells such as 
the macrophage, the osteoblast, and the mesenchymal precursor cell.  Our studies have 
reaffirmed the complexity of the relationship between leptin and bone and provided 
insight on its potential use as a therapeutic agent for bone tissue engineering.  It is now 
apparent that leptin modulation of bone formation is dependent on multiple factors such 
as gender, age, inflammatory state, and presence of central leptin resistance.  This results 
in diverse correlations between leptin and bone mineral density that range from a 
negative correlation prominent in males (Table 1) to a positive correlation often observed 
in post-menopausal females (Table 2).  Our studies revealed that this gender discordance 
may be related to leptin regulation of the myeloid lineage as our LysM
Cre+F/F
 transgenic 
mouse was the first to demonstrate a gender-specific leptin-related bone phenotype 
(Table 3).  We also determined that leptin regulation of osteoblast function is minimal at 
physiologic equilibrium, though positive effects are possible in vitro.  In addition, based 
on our studies with the 3.6
Cre+F/F
 animals we hypothesize that leptin may negatively 
regulate the differentiation of mesenchymal precursor cells.  Thus, in the context of leptin 
regulation of bone formation one is left with three negative modulators (brain, MPCs, and 
myeloid lineage) and two potentially positive modulators (osteoblast and myeloid 
lineage) (Figure 38).   
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The myeloid lineage is listed in both groups due to the divergent, gender-specific bone 
phenotype observed in the 42 week old LysM
Cre+F/F
 mice (Table 3).  The LysM promoter 
is known to drive deletion on myeloid lineage cells such as monocytes, macrophages, 
granulocytes and osteoclasts.  Thus, at this time, it is not possible for us to definitively 
determine the individual contribution of these cell types.  In addition, it is possible that 
the observed cortical changes in the 52 week old LysM
Cre+F/F
 males occurred due to their 
average 11% body mass increase (36g vs 39.6g, p=0.009, N=6).  However, this mass 
differential is far less than the 23% increase observed in the 42 week old 3.6
Cre+F/F
 males 
(37.2g vs 45.8g, p<0.001, N=6), yet the increases in cortical parameters are similar or 
more prominent in the aged LysM
Cre+F/F
 animals (Table 3, Table 6).  This lack of 
proportional increase of body mass and cortical values implies that impaired leptin 
signaling may be driving the changes in bone metabolism directly through the myeloid 
lineage of the LysM
Cre+F/F
 animals.  In summary, the diversity of our findings implies that 
leptin is not a likely candidate for direct bone tissue engineering.  However, the effects on 
the bone are minimal enough to consider its use for treatment of other disorders.   
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Figure 38.  Summary of leptin modulation of bone formation.  Circulating leptin has the ability to 
modulate bone formation both by acting centrally through the hypothalamus and by acting peripherally on 
individual cells.  Negative mediators of skeletal bone mass include the sympathetic nervous system, the 
mesenchymal precursor, and the myeloid lineage in males.  Positive modulators include the osteoblast and 
the myeloid lineage in females. 
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